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ABSTRACT  
Targeted drug delivery is achieved by enhancing drug availability at the response site 
while minimising its availability at other sites, especially those that manifest toxicity. 
The effects of liposomes and polymeric nanoparticles in cancer chemotherapy have 
been investigated in recent years and there have been some interesting outcomes 
resulting in improved survival rates of the patients. Thus, the present study was carried 
out to investigate the effect of encapsulating TMZ and Patrin-2 into liposomes and 
microparticles separately in order to enhance the delivery. 
 A validated HPLC system was used for the analysis of both TMZ and Patrin-2. First 
phase of our study involved the preparation of a delivery system of TMZ and Patrin-2 
through liposomes in order to enhance the treatment of glioma. It involved the 
application of freeze-thaw and dehydration-rehydration methods to encapsulate the 
TMZ into liposomes. However, the desired encapsulation efficiency (EE %) of TMZ 
was not achieved using these methods, the maximum entrapment achieved with     
freeze-thaw method was 11.54 ± 0.70 % while for dehydration-rehydration method was                      
26.69 ± 0.34 %. Therefore the second phase focussed on preparing polymeric 
microparticles for continuous delivery of intact TMZ and Patrin-2 using the spray dry 
method. The maximum entrapment achieved using this method for TMZ was 64.32 ± 
2.58 % while the maximum entrapment achieved for Patrin-2 was 68.47 ± 1.47 %, thus, 
this technique was found to be successful for the preparation of both TMZ and Patrin-2 
loaded PLGA microparticles. Furthermore the release study of both TMZ and Patrin-2 
was investigated using dispersion and dialysis methods. TMZ and Patrin-2 showed an 
initial burst release, however TMZ later showed decrease in concentration over the 
period of time while Patrin-2 showed a slow release with an increase in concentration.  
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This novel study aids in comparing various methods used for investigating the 
preparation of TMZ loaded liposomes, and TMZ and Patrin-2 loaded microparticles. In 
preparation of liposomes based on this research dehydration-rehydration was found to 
be a more efficient method than the freeze-thaw method for encapsulating TMZ, while 
the spray dry method was found to be more effective than the emulsifying solvent 
evaporation method in obtaining the maximum EE % for TMZ and Patrin-2 for 
preparation of microparticles. The release profiles of TMZ and Patrin-2 from the 
microparticles was studied using the dispersion method and the dialysis bag diffusion 
technique however due to tome being the limited factor the technique could not be 
explored completely. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
CONTENTS 
 
Declaration .................................................................. ..................................................2  
Abstract ....................................................................................................................... 3 
Contents....................................................................................................................... 5 
List of Figures .............................................................................................................. 9 
List of Tables ............................................................................................................. 11 
Acknowledgements .................................................................................................... 14 
Abbreviations ............................................................................................................ 16 
 
CHAPTER 1 Introduction ....................................................................................... 19 
1.1 Glioma ............................................................................................................. 20 
1.2 Temozolomide  ................................................................................................ 21 
1.3 Patrin-2 ............................................................................................................ 25 
1.4 Liposomes ........................................................................................................ 28 
    1.4.1 Applications of Liposomes ......................................................................... 30 
    1.4.2 Drug interaction with liposome .................................................................. 31 
    1.4.3 Phospholipids ............................................................................................ 33 
       1.4.3.1 Lα-phosphatidylcholine ........................................................................ 36 
       1.4.3.2 1,2-distearoyl-sn-glycerol-3-phosphocholine (DSPC) and  
            1,2-dimyristoyl-sn-glycerol-3-phohsphocholine (DMPC) ........................... 37 
       1.4.3.3 Lecithin derived from Soyabean ........................................................... 38 
       1.4.3.4 Phospholipon ® 90 H.  .......................................................................... 39 
       1.4.3.5 Cholesterol and Stearic acid.................................................................. 40 
    1.4.4 Techniques used in the current study for formation of liposomes ............... 41 
1.5 Microparticles.....................................................................................................42 
    1.5.1 Applications of microparticles ................................................................... 44 
    1.5.2 Poly (d,l-lactide-co-glycolide) (PLGA)........................................................45 
    1.5.3 Techniques used in the current study for formation.....................................47 
    1.5.4 Dissolution techniques used for determination of drug release from the 
 PLGA microparticles...............................................................................................48 
    1.5.5 Particle size analysis....................................................................................49 
1.6 High Performance Liquid Chromatography (HPLC)..........................................51 
6 
 
1.7 The main research questions and aims .............................................................. 54 
    1.7.1 Main aim ................................................................................................... 54 
    1.7.2 Specific aims of the research ...................................................................... 55 
 
CHAPTER 2 Materials and Methods ..................................................................... 56 
2.1 Materials .......................................................................................................... 57 
    2.2 Equipments ...................................................................................................... 59 
    2.3 HPLC methods ................................................................................................. 60 
       2.3.1 HPLC instrumentation ................................................................................ 60 
       2.3.1 HPLC column............................................................................................. 61 
       2.3.3 Validation of HPLC system ........................................................................ 61 
           2.3.3.1 Selection of Mobile phase ..................................................................... 61 
           2.3.3.2 Stock solution ....................................................................................... 62 
           2.3.3.3 Calibration curve (linearity testing of the HPLC system)....................... 62 
          2.3.3.4 Repeatability (Intraday analysis).. ......................................................... 62 
          2.3.3.5 Reproducibility ..................................................................................... 63 
           2.3.3.6 Limit of detection (LOD) and Limit of quantification (LOQ) ................ 63 
2.4 Stability test of TMZ and Patrin-2 .................................................................... 63 
        2.4.1 Standard solution ....................................................................................... 63 
2.4.2 Compatibility test of the two drugs TMZ and Patrin-2 ............................... 64 
2.5 To develop liposomal preparation of TMZ ....................................................... 64 
     2.5.1 Freeze-thaw method .................................................................................. 64 
        2.5.2 Dehydration-rehydration method ............................................................... 65 
2.5.3 Determination of EE % .............................................................................. 65 
2.6 Methods used for preparation of PLGA microparticles ..................................... 66 
2.6.1 Emulsifying-solvent evaporation method ................................................... 66 
2.6.2 Determination of EE % of the TMZ loaded PLGA microparticles .............. 67 
2.6.3 Spray drying method ................................................................................. 68 
  2.6.3.1 The preparation of TMZ loaded PLGA microparticles and Patrin-2 loaded 
PLGA microparticles.......................................................................................... 68 
  2.6.3.2 Determination of EE % of TMZ and Patrin-2 loaded PLGA           
microparticles..................................................................................................... 69 
2.7 Particle size analysis of liposome and microparticles ........................................ 70 
7 
 
2.7.1 Particle size analysis of liposome using the mastersizer ............................. 70 
        2.7.2 Particle size analysis of microparicles using the scanning electron  
        microscopy (SEM).................................................................................................71 
2.8 Dissolution techniques ..................................................................................... 72 
2.8.1 Dispersion method used for determination of release of TMZ and Patrin-2 
from the PLGA microparticles ........................................................................... 72 
2.8.2 Dialysis bag method used for determination of release of TMZ and Patrin-2 
from the PLGA microparticles ........................................................................... 73 
2.9 Statistical analysis ............................................................................................ 74 
 
CHAPTER 3 Results ................................................................................................ 75 
3.1 HPLC methods for TMZ and Patrin-2 analysis ................................................. 76 
    3.1.1 Linearity testing.............................................................................................77 
   3.1.2 Repeatability .............................................................................................. 79 
   3.1.3 Reproducibility...............................................................................................80 
   3.1.4 Limit of detection ....................................................................................... 81 
   3.1.5 Limit of quantification ................................................................................ 82 
    3.2 Stability test for TMZ and Patrin-2 ................................................................... 84 
        3.2.1 Compatibility test of TMZ and Patrin-2 carried out in mixture of PBS and             
      ethanol................................................................................................. ......................84            
    3.2.2 Dry sample reaction carried out for the determination of compatibility of    
         TMZ and Patrin-2..................................................................................................89 
  3.3 Results of attempted preparations of various liposome formulations using TMZ 
as the active compound .......................................................................................... 90 
         3.3.1 Freeze-Thaw method ................................................................................. 90 
        3.3.2 Dehydration-rehydration method ............................................................... 93 
3.3.3 A comparison between freeze-thaw and dehydration-rehydration methods 
used for the preparation of TMZ loaded liposomes ............................................. 96 
3.4 Preparation of PLGA microparticles using two procedures ............................... 97 
     3.4.1 Emulsifying solvent evaporation method ................................................... 97 
         3.4.2 Spray dry method ...................................................................................... 98 
    3.5 Particle size analysis of liposome and microparticles ...................................... 100 
3.5.1 Particle size analysis of liposome using the mastersizer ........................... 100 
8 
 
     3.5.2 Particle size analysis of liposome using the Scanning Electron microscopy     
(SEM).......................................................................................................................101           
    3.6 Dissolution techniques ................................................................................. ...103 
    3.6.1.1 Dispersion Method used for determining the release of TMZ from the 
PLGA microparticles................................................................................................103     
        3.6.1.2 Dispersion Method used for determining the release of Patrin-2 from       
           PLGA microparticles......................................................................................106 
3.6.2 Dialysis Bag Method used for determining the release of TMZ and Patrin-2 
from  PLGA microparticles...............................................................................109 
 
CHAPTER 4 Discussion ........................................................................................ 110 
4.1 Validation of HPLC system ............................................................................ 111 
4.2 Stability test of TMZ and Patrin-2 .................................................................. 111 
4.3 Attempted preparation of various liposome formulation of TMZ using Freeze-
Thaw and Dehydration and Rehydration method. ................................................. 112 
4.4 Preparation of PLGA microparticles using two different methods................... 115 
4.5 Particle size analysis of liposomes and microparticles .................................... 117 
4.6 Dissolution techniques ................................................................................... 118 
       4.6.1 Dispersion method used for determination of release of TMZ and Patrin-2   
       from the PLGA microparticles..............................................................................118 
       4.6.2 Dialysis Bag Method used for determination of release of TMZ and Patrin-2        
       from the PLGA microparticles..............................................................................121 
 
Conclusion..................................................................................................................123 
Future Prospects........................................................................................................125 
 
References .............................................................................................................. 127 
Appendix ................................................................................................................ 143 
 
 
 
 
 
 
9 
 
LIST OF FIGURES 
Figure 1.1 Chemical structure of Temozolomide with a single highly reactive site .... 21 
Figure 1.2 Mechanism of action of TMZ above pH 7 ................................................ 22 
Figure 1.3 DNA methylation sites ............................................................................. 23 
Figure 1.4 Use of Liposome and microparticles as drug carriers improves the effect of 
molecular active substances ....................................................................................... 25 
Figure 1.5 Chemical structure of Patrin-2  ................................................................. 26 
Figure 1.6 Action of TMZ and Patrin-2 causing MGMT and other DNA repair 
mechanisms to deal with DNA damage caused due to methylation of the TMZ, in 
human cells ................................................................................................................ 27 
Figure 1.7 Representation of the structure of liposome encapsulating a drug ............. 30 
Figure 1.8 Types of the drugs and site of their incorporation into liposomal vesicles . 32 
Figure 1.9 Chemical structure of Phospholipid .......................................................... 33 
Figure 1.10 The structure of Lα-phosphatidylcholine along with its fatty acid 
composition ............................................................................................................... 36 
Figure 1.11 The structure of DSPC and DMPC ......................................................... 37 
Figure 1.12 The structure of Lecithin along with its fatty acid composition ............... 38 
Figure 1.13 The structure of Phospholipon ® 90 H along with its fatty acid  
composition ............................................................................................................... 39 
Figure 1.14 The structures of (a) cholesterol and (b) stearic acid ............................... 40 
Figure 1.15 An illustration of particle size analyser ................................................... 42 
Figure 1.16 Representation of the structure of PLGA nanoparticle encapsulating  
a drug......................................................................................................................... 44 
Figure 1.17 Representation of the structure of PLGA ................................................ 46 
Figure 1.18 Functional principle of the drying air ...................................................... 47 
Figure 1.19 Schematic diagram of scanning electron microscopy .............................. 50 
Figure 1.20 Schematic diagram of HPLC .................................................................. 53 
 
Figure 2.1 High Performance Liquid Chromatography coupled with UV detector used 
for sample analysis..................................................................................................... 60 
Figure 2.2 Mini Spray Dryer used for preparation of microparticles .......................... 69 
Figure 2.3 Mastersizer 2000 used for particle size analysis... ..................................... 71 
Figure 2.4 Scanning electron microscopy (SEM) used for particle size analysis..........72 
10 
 
Figure 2.5 Preparation of the dialysis chamber to set the reaction................................74 
 
Figure 3.1 Calibration curve for TMZ and Patrin-2 ................................................ ...78 
Figure 3.2 HPLC chromatogram for the compatibility of TMZ and Patrin-2 at a concentration 
of 0.05 mg/ml (a) TMZ Standard solution in mobile phase (n = 3), (b) Patrin-2 standard 
solution in acetonitrile (n = 3) and (c) TMZ and Patrin-2 mixture in PBS and ethanol (ratio 
8:2) solution stored for 288 hr at 37°C  (n = 3)..........................................................................89   
Figure 3.3 Comparison between Freeze-Thaw and Dehydration-Rehydration         
method ....................................................................................................................... 96 
Figure 3.4 Spray dry method. .................................................................................... 99 
Figure 3.5 Particle size distribution. ........................................................................ 100 
Figure 3.6 Particle size analysis...................................................................................102 
Figure 3.7 Release pattern of TMZ from PLGA microparticles..................................105 
Figure 3.8  Release pattern of Patrin-2 from PLGA microparticles ......................... .108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
LIST OF TABLES  
 
Table 2.1 Materials used in this study ........................................................................ 57 
Table 2.2 Equipment used in this study................................................................. .....59 
Table 3.1 Linearity testing of TMZ and Patrin-2. Data values are the average of             
n = 3...............................................................................................................................77 
Table 3.2 The repeatability results for TMZ and Patrin-2 at a concentration of 0.02 
mg/ml. The mean of the 6 samples was calculated from which the SD and RSD values 
are obtained...................................................................................................................79 
Table 3.3 The reproducibility results for TMZ and Patrin-2 at a concentration of 0.02 
mg/ml. The mean of the 6 samples was calculated from which the SD and RSD values 
are obtained.Data are the average of n = 3....................................................................80 
Table 3.4 Limit of detection for TMZ and Patrin-2. Data values are the average of      
n=3................................................................................................................................81 
Table 3.5 Limit of quantification of TMZ and Patrin-2 at a concentration of 7.81 µg/ml 
was injected 6 times. The mean of the 6 injections was calculated from which the SD 
and RSD values are obtained ...................................................................................... 82 
Table 3.6 A summary of the parameters used to validate the analytical HPLC method 
for TMZ and Patrin-2 ................................................................................................. 83 
Table 3.7 The results for the stability of TMZ at a concentration of 0.05 mg/ml in PBS 
and ethanol (ratio 8:2) solution stored for (a) 72 hr (B) 288 hr at three different 
temperatures. The analysis of these samples was carried out using HPLC with mobile 
phase (35% acetonitrile consisting of 10 mM TBAA, 10 mM SDS and 25 mM citric 
acid). Data values are the average of n=3 ....................................................................85 
Table 3.8 The results for the stability of Patrin-2 at a concentration of 0.05 mg/ml in 
PBS and ethanol (ratio 8:2) solution stored for (a) 72 hr (B) 288 hr at three different 
temperatures.. The analysis of these samples was carried out using HPLC with mobile 
phase (35% acetonitrile consisting of 10 mM TBAA, 10 mM SDS and 25 mM citric 
acid). Data values are the average of n=3....................................................................86 
 
 
 
12 
 
Table 3.9 The results for the compatibility of TMZ and Patrin-2 at a concentration of    
0.05 mg/ml in PBS and ethanol (ratio 8:2) solution stored for (a) 72 hr (B) 288 hr at 
three different temperatures. The analysis of these samples was carried out using HPLC 
with mobile phase (35% acetonitrile consisting of 10 mM TBAA, 10 mM SDS and 25 
mM citric acid). Data values are the average of n=3 ................................................... 87 
Table 3.10 The results testing the compatibility of TMZ and Patrin-2 at a concentration 
of 0.05 mg/ml in PBS and ethanol solution. The analysis of this sample was carried out 
using HPLC with mobile phase (35% acetonitrile consisting of 10 mM TBAA, 10 mM 
SDS and 25 mM citric acid). Data values are the average of n=3 ............................... .90 
Table 3.11 Entrapment efficiency of TMZ loaded liposomes using different 
phospholipids using the Freeze-Thaw method. Data values + standard deviation,      
n=3. ........................................................................................................................... 91 
Table 3.12 Entrapment efficiency of TMZ loaded liposome with a combination of 
phospholipon 90 H and cholesterol and a combination of Lα-phosphatidylcholine and 
cholesterol using the freeze-thaw method. Data values + standard deviation, n=3...... .92 
Table 3.13 Entrapment efficiency achieved from TMZ loaded liposome with 
phospholipids in combination with cholestrol using the Dehyration-Rehydration 
method. Data values + standard deviation, n=3 .......................................................... 93 
Table 3.14 Entrapment efficiency achieved from TMZ loaded liposome with 
phospholipids in combination with cholestrol using the Dehyration-Rehydration 
method. Data values +standard deviation, n=3. .......................................................... 94 
Table 3.15 Entrapment efficiency achieved from TMZ loaded liposome with 
phospholipids mentioned in the table below in combination with stearic acid using the 
Dehyration-Rehydration method. Data values + standard deviation, n=3 .................... 95 
Table 3.16 The entrapment efficiencies achieved when TMZ was used to prepare 
PLGA microparticles using the emulsifying solvent evaporation method and varying the 
MW of PLGA. The PLGA with a MW of 1.7 × 10
4
 Da showed the maximum 
entrapment with TMZ. Data values +standard deviation, n=3 ............................ .........97 
Table 3.17 The entrapment efficiency obtained from TMZ loaded PLGA microparticles 
and Patrin-2 loaded PLGA microparticles by varying the MW of PLGA using the Spray 
Dry method with PLGA of MW 1.7 × 10
4
 Da showed the maximum entrapment with 
TMZ. Data values +standard deviation, n=3 ............................................................... 98 
13 
 
Table 3.18 From HPLC analysis TMZ release from PLGA microparticles was detected 
and from the peak area obtained the cumulative mass and cumulative % release was 
calculated. Data values are the average of n=2 ......................................................... 104 
Table 3.19 Patrin-2 released from PLGA microparticles was detected and from the peak 
area obtained the cumulative mass and cumulative % release was calculated. Data 
values are the average of n=2 .................................................................................. .107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
ACKNOWLEDGEMENTS 
In the name of the almighty “ALLAH” 
It would not have been possible to write this M.Phil thesis without the help and support 
of the kind people around me, to only some of whom it is possible to give particular 
mention here. 
This thesis is dedicated to my father Gulam Dastagir Parkar, who taught me that the best 
kind of knowledge to have is that which is learned for its own sake. It is also dedicated 
to my mother Shahida Parkar, who taught me that even the largest task can be 
accomplished if it is done one step at a time. Without their encouragement and 
understanding it would have been impossible for me to finish this work. My special 
gratitude is due to my brother, my sisters and their families for their loving support. My 
loving thanks are due to my 3 nieces Iffah, Adina and Sana. 
In the first instance I would like to express my deep and sincere gratitude to my 
supervisor, Dr. Leroy Shervington for his enthusiasm, his inspiration, and his great 
efforts to explain things clearly and simply. He has helped to make this research fun for 
me. It was only due to his valuable guidance, support, great understanding and ever-
friendly nature that I was able to complete my research work in a respectable manner. It 
has been a distinct privilege for me to work under his supervision.  
I wish to express my warm and sincere thanks to Dr. Amal Shervington for her valuable 
support and advice on both academic and a personal level, for which I am extremely 
grateful. 
My sincere thanks are due to Prof. Jai Paul Singh and Dr. Abdelbary Elhissi for their 
help and support for this study. 
15 
 
I would also like to express my gratitude to my colleagues in Room MB212; Seema 
Jaiswal, Mayur Gawde, Shweta Kamble and Pooja Babar for the many discussions we 
had, be they research-related or not, were often the occasion for new discoveries and 
always truly agreeable moments. They have always maintained a great working 
atmosphere with no end of fun, advice, as well as good moral support.   
During this work I have collaborated with many colleagues for whom I have great 
regard, and I wish to extend my warmest thanks to all those who have helped me with 
my work in the Department of Pharmacy and Biomedical Sciences. I would especially 
like to thank James Donnelly for giving valuable knowledge about HPLC. I would like 
to acknowledge the financial, academic and technical support of the University Central 
Lancashire. The library facilities of the University have been indispensable. 
This thesis would never have taken shape without the inspired problem solving of 
Mayur Gawde and the detailed review, constructive criticism and excellent advice by 
Shantaram Muthaye, Paresh Patel and Nirav Nagda during the preparation of this thesis. 
Without friends, life as an international student would not be the same. As I got to know 
few of the closest people I have been with in these years, I would like to thank Shweta 
Naik, Zarine Khan (for the delicious food), Sukhmander Kaur and Chinmay Munje for 
helping me get through the difficult times, and for all the emotional support, 
entertainment, and caring they provided.  
 
"If A equals success, then the formula is: A = X + Y + Z, X is work. Y is play. Z is keep 
your mouth shut." Albert Einstein 
 
 
16 
 
LIST OF ABBREVIATIONS        
 
4BTG 
 
O
6
-(4-bromothenyl) guanine  
(Patrin-2) 
AIC 5-aminoimidazole-4-carboxamide 
 
AP 
 
Apurinic/Apyrimidinic 
ATase 
 
Alkyltransferase 
BCNU 
 
Carmustine 
BER 
 
Base Excision Repair 
CCNU 
 
Lomustine 
Da Dalton 
 
DMPC 1,2-distearoyl-sn-glycerol-3-phosphocholine 
  
DNA 
 
Deoxyribonucleic acid 
DSPC 1,2-dimyristoyl-sn-glycerol-3-phosphocholine  
 
EE % Encapsulation Efficiency 
 
GA Glycolide 
 
GUVs Giant Unilamellar Vesicles 
 
HPLC High Performance Liquid Chromatography 
 
hr Hour 
 
LOD Limit of Detection  
 
LOQ Limit of Quantification 
 
LUVs Large Unilamellar Vesicles 
 
MGMT 
 
O
6
-methylguanine-DNA methylltransferase 
min Minute 
 
MLVs Multilamellar Vesicles 
 
MMR Mismatch Repair 
 
17 
 
MPA Mean Peak Area 
 
MPG 
 
Methylpurine glycosylase 
 
MTIC 
 
Methyltriazen-1-yl imidazole-4-carboxamide 
 
MVVs Multivesicular Vesicles 
 
MW Molecular Weight 
 
MX Methoxyamine 
 
N
7
-meG 
 
N
7
-methylguanine 
 
N
7
-meGDNA 
 
N
7
-methylguanine DNA 
 
N/A Not Applicable 
 
O
6
-BG 
 
O
6
-benzylguanine 
 
O
6
-meG 
 
O
6
-methylguanine 
 
O
6
-meGDNA 
 
O
6
-methylguanine DNA 
 
PBS Phosphate Buffer Saline 
 
PC Phosphatidylcholine 
 
PE Phosphatidylethanolamine 
 
PG Phosphatidylglycerol 
 
PLA Polylactide 
 
PLGA Poly(d,l-lactide-co-glycolide) 
PVA Polyvinyl Alcohol 
 
rpm Rotations Per Minute 
 
RSD Relative Standard Deviation 
 
RT Retention Time 
 
SD Standard Deviation 
 
SDS Sodium Dodecyl Sulphate 
 
SEM Scanning Electron Microscopy  
18 
 
SUVs Small Unilamellar Vesicles 
 
TBAA Tetrabutylammonium Acetate 
 
TMZ 
 
Temozolomide 
UDP Unidentified Product 
 
ULVs Unilamellar Vesicles 
 
USP  United States Pharmacopoeia 
 
WHO 
 
World Health Organization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION 
  
20 
 
1.1 Glioma 
Gliomas are the most frequent primary brain tumours, derived from glial cells of astrocytic, 
oligodendroglial and ependymal origin. Glial cells are the supporting cells of central 
nervous system, providing the support and nourishment to the neural cells in the brain 
(Trent et al., 2002). Glial cells show an ability to undergo cell division and on loss or 
uncontrolled cell division giving rise to tumour known as glioma.  Gliomas start in the 
brain or spinal cord tissue and do not spread to other areas of the body but can spread 
within the nervous system and can be either benign or malignant (Sawyer et al., 2006). 
Since there are mainly three types of glial cells, glioma is also of three types namely- 
astrocytoma, ependymoma and oligodendroglioma. A fourth type of glioma is also 
present, mixed glioma, and is a mixture of the other types. Gliomas have been defined 
pathologically as tumours that display histological, immunohistochemical, and 
ultrastructural features of glial differentiation (Chang et al., 2005). Based on pathological 
and histological appearance, glioma can be classified into different grades. The most 
widely used classification of human gliomas is that of World Health Organisation (WHO), 
revised in year 2000 (Kleihues et al., 2002). According to the WHO classification of brain 
tumours gliomas are divided in low-grade (grades I and II) and high-grade (grades III and 
IV) tumours (Scott et al., 1998). Low grade tumours are well differentiated, nonanaplastic, 
benign tumour showing better prognosis, where as high grade tumours are undifferentiated, 
highly aggressive, anaplastic and malignant tumour showing very poor prognosis      
(Maher et al., 2001). Surgery, radiotherapy and chemotherapy are the most commonly used 
treatments for gliomas, however none of these procedures have been able to cure the 
disease due to the diffuse nature of gliomas (Bobola et al., 2004). These procedures are 
sometimes used in a combination to improve the survival and quality of life                  
(Cher et al., 2008). Several randomized clinical trials have showed that median survival to 
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be longer with radiation and chemotherapy (Sandberg-Wollheim et al., 1991). The most 
commonly used drugs in chemotherapy include Temozolomide (TMZ), Carmustine 
(BCNU), and a three drug combination of Procarbazine, Lomustine (CCNU) and 
Vincristine, together abbreviated as (PCV) (Westphal et al., 2003; Stupp et al., 2005). 
1.2 Temozolomide  
TMZ is an oral alkylating agent which has a single highly reactive site (Fig. 1.1). It can 
readily cross the blood brain barrier (Newlands et al., 1992; Darkes et al., 2002), and 
has proved to be active against variety of tumour type in vitro as well as in vivo. Due to 
its acid-stability and lipophilic character, TMZ taken orally has a bioavailability of 
≈100% (Darkes et al., 2002).  
N
N
N
N
N
H3C
NH2
O
O
2
3
4
5
6
1
 
Figure 1.1 Chemical structure of Temozolomide with a single highly reactive site (The 
chemical structure was drawn using the chemdraw ultra 12.0 software). 
TMZ is a modified form of imidazotetrazinones and is also chemically associated to 
dacarbazine and is the 3-methyl derivative of an anticancer drug mitozolomide 
(Newlands et al., 1997). TMZ is found to be unstable above pH 7 and is instantaneously 
hydrolysed to methyltriazen-1-yl imidazole-4-carboxamide (MTIC) (Lowe et al., 1992). 
Assimilation in the intestine results in the electropositive carbonyl at C4 position 
located in the tetrazinone ring in TMZ being disposed to nucleophilic attack by water 
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(Denny et al., 1994). The resulting ring cleavage with the loss of carbon dioxide leads to 
the development of methyltriazen-1-yl imidazole-4-carboxamide (MTIC) which then 
undergoes further break down to an inactive carboxylic acid derivative,                          
5-aminoimidazole-4-carboxamide (AIC), and a highly reactive methyldiazonium ion 
(Fig. 1.2) (Clark et al., 1995). The methyldiazonium ion methylates guanine residues in 
guanine-rich regions (Friedman et al., 1998). Methylation at the O
6
 position of guanine 
in genomic DNA is an important step as damage caused by methylation at guanine O
6
 
are usually repaired by the enzyme O
6
-methylguanine-DNA methyltransferase (MGMT) 
(Fig. 1.3). Each time a DNA lesion is repaired one molecule of the MGMT enzyme goes 
into a non-functional state (Margison et al., 2005). If TMZ is taken on a regular basis 
the repair protein is eradicated each time and more damaging DNA lesions will be 
amassed (Friedman et al., 1998). 
N
NN
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CH3
H2N
O
O
N
NH
O
N
H
N
N
H
N
N
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O
H2N
H2N
AIC
+ CH3N
+
2
Temozolomide
Chemical 
conversion 
at Phsiological 
pH
MTIC
 
Figure 1.2 Mechanism of action of TMZ above pH 7 (The chemical structure was drawn using 
the chemdraw ultra 12.0 software). 
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Many brain cancer types do not express the MGMT enzyme (Friedman et al., 1998). 
However, certain types of cell lines and xenografts express high concentrations of the 
MGMT enzyme and show resistance to TMZ exposure (Brada, 2002). Damage occurs 
due to mutation and those that cannot be repaired by MGMT are identified by mismatch 
repair (MMR) enzymes, which recover the mismatch caused in the daughter strand by 
removing the thymine base from O
6
-methylguanine (O
6
meg): thymine base pairs. 
However, MMR enzymes are not always successful in performing their task and 
eventually cause breaks and nicks in the daughter strands (Hirose et al., 2001). This 
event leads cell arrest at the G2/M phase prior to apoptosis. TMZ, similar to other 
alkylating agents have an effective antitumour activity for the replicating cells         
(D’Atri et al., 1998; Darkes et al., 2002).  
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Figure 1.3: DNA methylation sites (The chemical structure was drawn using the chemdraw 
ultra 12.0 software). 
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The three main DNA repair mechanisms responsible for TMZ resistance are: elevated 
intracellular levels of MGMT; a deficient mismatch repair process (MMR); and base 
excision repair pathway (BER) with activation of the poly (ADP)-ribose polymerase 
protein (Tentori et al., 1997). Primary resistance to TMZ is directly correlated to high 
MGMT levels but in MGMT-deficient cells, low or deficient MMR protein levels 
become important in conferring resistance (Darkes et al., 2002). One of the ways of 
enhancement of TMZ activity is by direct inactivation of ATase. From previous studies, 
ATase inactivator O
6
-(4-bromothenyl) guanine (4BTG, also known as Patrin-2) used in 
in vivo studies as a pre-treatment to the mouse melanoma model has shown to improve 
the antitumor effect of TMZ without any additional toxicity (Brock et al., 1998). 
TMZ, despite its advantages also shows limitations in its use as an anticancer reagent. 
TMZ is found to develop unusual cardiomyopathy, acute toxicity which leads to 
myelosuppression and oral ulcerations when it binds to the site other than the target site 
(Huang et al., 2008). In order to prevent these consequences and to obtain better 
efficacy, it is important to develop a treatment that enables the drug to reach directly to 
the site of action (Yang et al., 1999). Studies have shown that the use of colloidal 
substances such as microemulsions, liposomes, niosomes and polymeric nanoparticles 
as drug carriers have significantly helped to overcome these drawbacks such as acute 
and chronic toxicity or low stability by decreasing the number of dosage of the drug 
(Muller et al., 2000; Huang et al., 2008). Furthermore, liposome and microparticles also 
help to attain controlled release of TMZ (Allen and Cullis, 2004). Thus one of the main 
aims of this study is to prepare a delivery system of TMZ in order to decrease its 
toxicity and side effects (Fig. 1.4) (Menei et al., 1996; Menei et al., 1997). TMZ is 
usually required in high doses to attain the therapeutic brain levels because of its short 
half life that is 1.8 hr in plasma (Reni et al., 2004; Zhang and Gao, 2007).
 
Thus, 
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resulting insufficient doses reaching the target site. These problems could be overcome 
to some degree by use of liposomes or microparticles for the drug delivery as their use 
reduces the high amount of temozolomide intake in the body which is the reason of side 
effects (Ostro, 1983; Moghimi and Davis, 1994). 
 
Figure 1.4 Use of liposome and microparticles as drug carriers improves the effect of molecular 
active substances (Modified from http://ubm.opus.hbz-nrw.de/volltexte/2009/1880/pdf/diss. 
pdf). 
 
1.3 Patrin-2 
In order to further enhance the TMZ activity there is a need to use a drug/substrate 
which would support its mechanism of action and increase the sensitivity of 
chemotherapy. Patrin-2 is a compound that has recently been introduced into clinical 
studies (Turriziani et al., 2006). Patrin-2 is a non-hazardous pseudo substrate with     
low-molecular weight and has the ability of inactivating MGMT (Fig. 1.5)              
(Khan et al., 2008). Patrin-2 has also proved to be better tolerated than                        
O
6
-benzylguanine (O
6
-BG) derivative (Bobola et al., 2005; Woolford et al., 2006).  
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Figure 1.5 Chemical structures of Patrin-2 (The chemical structure was drawn using the 
chemdraw ultra 12.0 software). 
It has mainly been used in combination with triazene compounds to enhance their           
anti-tumour efficacy against different types of tumour cells endowed with elevated 
MGMT activity (Barvaux et al., 2004 a and b; Clemons et al., 2005). When a 
combination of Patrin-2 and TMZ was used, Patrin-2 showed sensitisation of human 
tumour xenografts of the methylating compounds (Middleton et al., 2002). 
The DNA damage caused by TMZ or other methylating therapeutic drug in human cells 
is usually repaired by MGMT and other DNA repair mechanisms (Papouli et al., 2004). 
Such methylating therapeutic drugs cause possible DNA lesions such as                      
O
6
-meG and N
7
-methylguanine (N
7
-meG) which are cytotoxic in nature (Fig. 1.6). 
MGMT by means of covalent transfer of the alkyl group to cysteine the conserved 
active site, removes the O
6
-alkylguanine DNA adduct and thus restoring the guanine to 
normal. In this process MGMT is inactivated by receiving the methyl group from        
O
6
-meG and is subjected to ubiquitin-mediated degradation. Similarly when MGMT 
transfers and accepts an alkyl group from Patrin-2 or O
6
-BG it becomes inactivated and 
is degraded thus, MGMT is also called as suicidal enzyme (Pearson et al., 2005). When 
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an O
6
-meG DNA adducts escape from MGMT repair, during DNA replication                  
O
6
-meG DNA forms a base pair with thymine. This base pairing is recognised by the 
MMR pathway causing futile cycles of repair which leads to cell death. N
7
-meG DNA 
adducts formed by TMZ (>70% of total DNA adducts) are successfully repaired by the 
BER pathway. The BER pathway contribution to the cytotoxicity of TMZ is only 
minimum. In this pathway, methylpurine glycosylase (MPG) binds methoxyamine 
(MX) to AP (apurinic/apyrimidinic), sites which are refractory to AP endonuclease 
cleavage, causing blockage of the BER pathway (Fig. 1.6). This causes disrupted 
replication, strand breakage and increased cytotoxicity of TMZ (Bobola et al., 2004;  
Liu and Gerson, 2006). 
 
Figure 1.6 Action of TMZ and Patrin-2 causing MGMT and other DNA repair mechanisms to 
deal with DNA damage caused due to methylation of the TMZ, in human cells                        
(Liu and Gerson, 2006). 
 
Thus, the anti-tumour activity of methyl-triazene compounds such as TMZ mainly 
depends on the production of methyl adducts to O
6
 or N
3
 or N
7
 of purine bases of DNA 
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(Philip et al., 1996; Tentori & Graiziani et al., 2002; Bodell et al., 2003). The two DNA 
repair enzyme systems, MGMT and MMR, play crucial roles in circumstancing the 
cytotoxic effects of methyl-triazene compounds (Pegg et al., 1983; Dolan et al., 1990; 
Pegg, 2000; Gerson, 2004; Trivedi et al., 2005; Morimoto et al., 2005;               
Turriziani et al., 2006). Resistance to triazenes is attributed to the high levels of MGMT 
related with target cells, while MMR aids the cytotoxic effect of these agents        
(Esteller et al., 2000; Fedier and fink, 2004). Resistance to the triazenes such as TMZ 
caused by MGMT can markedly be decreased in vitro and in vivo by use of the pseudo 
substrate Patrin-2 (Middleton et al., 2000; Kaina and Christmann, 2002). Based on these 
studies, the present study was carried out to investigate the effect of encapsulating TMZ 
and Patrin-2 into liposomes and microparticles separately and in combination in order to 
enhance the cytotoxicity of TMZ. Some work has been carried out to investigate the 
effects of liposome and polymeric nanoparticles on cancer chemotherapy and there have 
been some interesting outcomes regarding reduced side effects and can result in 
improved survival rates of the patients (Kitamura et al., 1996; Ranson et al., 2007). 
 
1.4 Liposomes 
Liposomes were discovered by A. Bangham and his team about 45 years ago and ever 
since then they developed into versatile tools in biology, medicine and biochemistry. 
Liposomes are the smallest artificial vesicles of spherical shape that can be produced 
from natural untoxic phospholipids and cholesterol (Bangham et al., 1965). Liposomes 
can be defined as a particular kind of vesicles or any structure formed by lipid bilayers 
which are capable to enclose a volume of the substance (Ostro, 1983; Connor & Huang, 
1986). These amphipathic molecules constitute one or more hydrophobic chains, one 
hydrophilic region where hydrophilic region forms the head group while the 
hydrophobic region form the tail. When suspended in an aqueous medium they 
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instinctively form bilayer vesicles (Gomez-hens and Fernandez-Romero, 2006). The 
basic structure of liposomes comprises of hydrocarbon chains which lean towards each 
other while the polar head groups are in contact with encapsulated and surrounding 
aqueous medium (Fig. 1.7) (Storm and Crommelin, 1998; Gomez-hens and Fernandez-
Romero, 2005). The structure of the liposomes can be determined by the number of 
bilayers present. Single bilayers (lamella) liposomes are called unilamellar vesicles 
(ULVs), while liposomes containing more than one bilayer are multilamellar vesicles 
(MLVs). Other liposomes consisting of small vesicles incorporating large vesicle are 
known a multivesicular vesicles (MVVs) (Gomez-hens and Fernandez-Romero, 2005). 
The entrapment of active compounds also depends on the different sizes of liposomes 
ranging from nanometre (nm) to micrometre (µm), such as small unilamellar vesicles 
(SUVs, 25-50 nm), large unilamellar vesicles (LUVs, 100 nm-1 µm), giant unilamellar 
vesicles (GUVs, 1.0-200 µm), multilamellar vesicles (MLVs, 0.1-15 µm), and multi-
vesicular vesicles (MVVs, 1.6-10.5 µm) (Silva et al., 2010). Liposomes can usually be 
stored in a buffer at pH 7.4 and at temperature approximately 4 °C for 5-7 days. 
However, storage time depends on a number of factors which include temperature, pH 
and medium (Oberholzer et al., 1999).  
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Figure 1.7: Representation of the structure of liposome encapsulating a drug (Modified from 
http://en.wikipedia.org/wiki/File:Liposome.jpg). 
 
1.4.1 Applications of liposomes 
Liposomes are mainly used as delivery systems for many substances which can easily 
be entrapped or act as anchor to various substituents (Gregoriadis, 1974). Liposomal 
delivery systems are well-known procedures used for encapsulation of anticancer and 
antimicrobial drugs, enzymes and antigens (Felnerova et al., 2004). The application of 
liposomes in the delivery systems aid in processes such as transport, distribution, 
controlled release, protection and localization of encapsulated drugs (Gregoriadis, 1974; 
Egger et al., 2001). In order to improve the performance of the enclosed drug, it is 
useful to consider the basic reasons for applying liposome as drug carriers             
(Storm and Crommelin, 1998).  
Some of the features of liposomes:  
Targeting- Liposomes when modified can enhance the therapeutic efficacy (drug 
targeting, site-specific delivery) of the drug by directing it to the target site in the body.  
Similarly, liposomes may also prevent the drug to target other body sites that are 
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particularly sensitive to the toxic action of the drug (site-avoidance delivery) (Cagnoni, 
2002). 
Duration- The material encapsulated in liposomes is slowly liberated. Such prolong 
processes help to maintain the therapeutic drug levels in the bloodstream and decreases 
the frequency of administration (Storm and Crommelin, 1998; Grant et al., 2001; 
Yowell & Blackwell, 2002).  
Protection- Liposomes protect the encapsulated compounds against other unfavourable 
aspects such as degradative enzymes existing in the host. Also the liposomes protect the 
body from toxic effects of the drugs (Hattori et al., 2004). 
Internalisation- One of the most beneficial aspects is the interaction of liposomes with 
target cells enhancing the delivery of the drug intracellularly which is critical for the 
non-encapsulated drugs due to the incompatible physiochemical characteristics         
(e.g. DNA molecules) (Vail et al., 2004).  
The cavity of the liposomes can be filled with drugs or other therapeutic agents. One of 
the functions of liposomes is the efficient delivery of biologically active compounds 
into the cells (Esposito et al., 2003).
 
Endocytosis appears to be the principal pathway by 
which liposomes enter cells to release the encapsulated drug and it is interesting to note 
that the pH of endocytotic vesicles is slightly acidic (Xu & Szoka, 1996). 
1.4.2 Drug interaction with liposome  
Liposomes, because of their biphasic character, can act as carriers for both lipophilic 
and hydrophilic drugs. Depending upon their solubility and partitioning characteristics, 
the drug molecules are located differently in the liposomal environment and exhibit 
different entrapment and release properties (Fig. 1.7). Based on the solubility, the drugs 
can be divided into four classes (1) highly hydrophilic, (2) highly lipophilic,                
(3) amphiphilic drugs that exhibit good biphasic solubility, and (4) drugs that exhibit 
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biphasic insolubility (Gulati et al., 1998). Thus, different drugs depend on different 
types of methods in order to be encapsulated as shown in Fig.1.8. The main feature of 
the method is the medium in which the compound is to be dissolved (Gomez-hens and 
Fernandez-Romero, 2006). Highly lipophilic drugs can be encapsulated almost entirely 
in the lipid bilayer of the liposomes (Vadiei et al., 1989). Since they are very weakly 
soluble in water, problems such as leakage of entrapped drug on storage are negligible. 
The most problematic compounds for liposomal entrapment are drug molecules that 
possess poor biphasic solubility. Being insoluble in both aqueous or lipid phases results 
in insufficient inadequate uptake by the liposomes (Goyal et al., 2005). The 
encapsulation efficiency of hydrophilic or other drugs that show weak encapsulation can 
be enhanced by making them lipophilic through the addition of hydrophobic side chains 
or by the addition of external compounds such as lactose or sodium chloride           
(Gulati et al., 1998). 
 
Figure 1.8 Types of the drugs and site of their incorporation into liposomal vesicles (Gulati et 
al., 1998). 
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1.4.3 Phospholipids 
The phospholipid composition and the capability of binding to other chemical species is 
one of the main features of their use in liposome formation (Rachev et al., 2001; 
Gomez-hens and Fernandez-Romero, 2005). Phospholipids are part of all cell 
membranes and play an important role in the signal transduction mechanism. The 
phospholipid structure consists of phosphoric residue, hydrophilic head and 
hydrophobic tail (Fig. 1.9). The hydrophilic head consists of the phosphate group, 
glycerol back bone, choline, ethanolamine and inositol, with different chemical 
properties. When exposed to an aqueous environment, phospholipids tend to form 
unique assemblies called "bilayers". The hydrophilic heads of the phospholipids turn 
towards the water molecules while the hydrophobic tails hide from water molecules.   
 
Figure 1.9 Chemical structure of Phospholipid (Adapted from http://kvhs.nbed.nb.ca/gallant/ 
biology/phospholipid_structure.jpg).  
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There are two basic sources of phospholipids: synthetic and natural. Natural lipids are 
generally either egg-derived or bovine-derived. Regardless of the regulatory issues, 
animal-derived products do not offer any advantages to synthetic lipids. They are 
inherently less stable due to the polyunsaturated fatty acids, and in most cases the 
synthetic counterpart costs the same or less than the tissue-derived product              
(Lasic, 1992). Synthetic lipids from different sources are not necessarily equal either. 
Synthetic lipids can be prepared from glycerol or glycero-3-phosphocholine (GPC) 
derived from a plant or animal source (Perrie and Gregoriadis, 2000). The latter is 
sometimes referred to as semi-synthetic lipid because a portion of the molecule is 
derived from a natural source (Harrington et al., 2002). Lipids derived from glycerol 
require the chiral centre be synthetically prepared which may lead to stereochemical 
impurities present in the final product (Gregoriadis, 1974). The typical plant source for 
GPC is soybean lecithin. This type of compound is synthesized by converting a natural 
PC into an acyl group through a chemical reaction. A highly pure, high-quality 
hydrogenated soy phospholipids that can assist you in developing new products is 
generally obtained from carefully selected, non-genetically modified soybeans as a 
source of raw materials (Lasic, 1992). 
Phospholipids derived from natural sources are mostly used as the parental liposome 
formation. Such phospholipids include phosphatidylcholine (PC), phosphatidylglycerol 
(PG) and phosphatidylethanolamine (PE) (Harrington et al., 2002). These phospholipids 
contain certain acyl chains which differ with source of origin, for example acyl chain 
found in egg PC is different to acyl chain in soy bean PC. Phospholipids also possess 
lyso-phospholipids where the acyl chain is located at C1-position of 
glycerophosphocholine and the other is eliminated by hydrolysis (Sessa and 
Weissmann, 1968). In addition, peroxidation can occur if unsaturated bonds are present 
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in the acyl chains. In the early 1980s the quality of lipids of several suppliers differed 
both qualitatively as well as quantitatively (Zuidam, 1993; Zuidam, 1996). However, 
the supplies nowadays are more consistent with high quality products. An interesting 
feature of liposomes is that their mechanical properties can be changed by incorporating 
a wide range of substances into their structure such as cholesterol and stearic acid 
(Rachev et al., 2001). The phospholipids used in this study are lα-phosphatidylcholine, 
1,2-distearoyl-sn-glycerol-3-phosphocholine (DSPC), 1,2-dimyristoyl-sn-glycerol-3-
phosphocholine (DMPC), lecithin and phospholipon 90H. These phospholipids can also 
be classified as natural and synthetic phospholipids where lα-phosphatidylcholine and 
lecithin are obtained naturally while DSPC, DMPC and phospholipon 90H are derived 
synthetically. 
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1.4.3.1 Lα-phosphatidylcholine 
Lα-phosphatidylcholine has an important function in the maintenance of integrity of the 
cell-membrane. It has also been recognized as an important signalling molecule        
(Exton, 1994). Lα-phosphatidylcholine comprises of phosphatidylcholine as its major 
component, it is a pure form of soyabean phospholipids. Its structure comprises of 
saturated as well as unsaturated fatty acids. Its phase transition temperature was 
reported to be unstable ranging between 55-65 °C and fatty acid composition was 
provided by the supplier Sigma Aldrich, UK. It comprises of 13 % palmitic acid, 4-6 % 
stearic acid, 10 % oleic acid, 64 % linoleic acid and 6-8 % linolenic acid. 
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Figure 1.10 The structure of Lα-phosphatidylcholine along with its fatty acid composition (The 
chemical structure was drawn using the chemdraw ultra 12.0 software). 
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1.4.3.2 1,2-distearoyl-sn-glycerol-3- phosphocholine (DSPC) and 1,2- dimyristoyl-
sn-glycerol-3-phosphocholine (DMPC) 
DSPC and DMPC are like chain phosphatidylcholine induced by variety of additives 
including glycerol, methanol, ethylene glycol, benzyl alcohol, chlorpromazine, 
tetracaine, ethanol, thiocyanate ion (Fig. 1.11) (McDaniel et al., 1983;                
McIntosh et al., 1983; Cunningham & Lis, 1986; Slater & Huang, 1988). The phase 
transition temperature of DSPC was 53 °C and of DMPC was 23 °C. 
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Figure 1.11 The structure of DSPC and DMPC (The chemical structure was drawn using the 
chemdraw ultra 12.0 software). 
 
 
 
 
 
 
 
38 
 
1.4.3.3 Lecithin derived from Soybean 
Lecithin is composed of a mixture of phospholipids: phosphatidylcholine, 
phosphatidylethanolamine, lysophosphatidylcholine, n-acyl-phosphatidylethanol- amine 
and phosphatidylinositol. Its fatty acid composition comprises of 12-17 % palmitic acid,   
2-5 % stearic acid, 11-15 % oleic acid, 59-70 % linoleic acid and 3-7 % linolenic acid 
(Fig. 1.12). Its phase transition temperature was reported to be 65 °C and fatty acid 
composition was provided by the supplier Sigma Aldrich, UK. 
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Figure 1.12 The structure of Lecithin with palmitic and linoleic acid chain attached to it along 
with its fatty acid composition (The chemical structure was drawn using the chemdraw ultra 
12.0 software). 
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1.4.3.4 Phospholipon
®
 90 H 
Phospholipon
®
 90H is hydrogenated form of lecithin product derived from soybean. 
Phospholipon
®
90H comprises of phospholipids such as hydrogenated                
phosphatidylcholine and hydrogenated lysophosphatidylcholine. Its fatty acid 
composition comprises of 15 % palmitic acid and 85 % stearic acid (Fig. 1.13). Due to 
its composition phospholipon 90H is found to be more stable than phosphatidylcholine 
and is also been previously used as for application of liposomes (Glavas-Dodov et al., 
2005; Parmar et al., 2010).  Its phase transition temperature was reported to be 54 °C 
and fatty acid composition was provided by the supplier Phospholipid GmbH, Germany. 
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Figure 1.13 The structure of Phospholipon
®
 90H along with its fatty acid composition (The 
chemical structure was drawn using the chemdraw ultra 12.0 software). 
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1.4.3.5 Cholesterol and Stearic acid 
Cholesterol, is an alternative habitual component of the liposome structure and a natural 
constituent of the biological membranes, whereas stearic acid is a saturated form of fatty 
acid, cholesterol and stearic acid play an important role in controlling the fluidity and 
the permeability of the artificial vesicle i.e. it makes the membranes more rigid thus 
avoiding leakage of the encapsulated compound (Fig. 1.14) (Gomez-hens and 
Fernandez-Romero, 2005; Perrie and Gregoriadis, 2000). In order to improve the 
rigidity of the liposome, cholesterol and stearic acid were combined with other 
phospholipids to form liposome formulations. 
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Figure 1.14 The structures of (a) cholesterol and (b) stearic acid (The chemical structure was 
drawn using the chemdraw ultra 12.0 software). 
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1.4.4 Techniques used in the current study for formation of Liposomes 
Methods such as freeze-thaw and dehydration-rehydration form liposomes that are 
multilamellar vesicle (MLVs). These MLVs possess greater encapsulating capacity, in 
addition to variation in vesicle size, size dispersion and lamellarity (Gabriels, 2003; 
Moscho, 1996). These factors are based on the type of the lipids used and their 
distribution efficiency. Repetition of these mechanical cycles such as freeze-thaw cycles 
or dehydration-rehydration cycles converts the initial MLV dispersion into other 
liposomes of different sizes (Gomez-hens and Fernandez-Romero, 2005). The freezing 
process aids in the encapsulation of TMZ inside the liposomal vesicle while the thawing 
breaks the multilamellar vesicles and promotes mixing of the encapsulated content on 
release (Shazly et al., 2008). Similarly dehydration causes fusion of the vesicle, 
liposomes are concentrated by the drying process and fuse to form multilamellar planes 
forming a sandwich of the drug between the resulting lamellae. To further disperse the 
vesicles, the addition of PBS and vortexing is carried out (Ostro, 1983). The TMZ 
loaded liposomes were then analysed for encapsulation by the application of HPLC.  
Particle size analysis  
The performance of laser diffraction depends on the particles passing through a laser 
beam scattering light at an angle that is inversely proportional to their size (large 
particles scatter light at low angles, whereas, small particles scatter light at high angles). 
Thus, to calculate particle size distribution, the intensity of light scattered from a sample 
is measured as a function of the angle (Fig. 1.15) (Ingebrigtsen and Brandl, 2002). The 
laser diffraction analyser was used in this study to measure the size of the TMZ loaded 
liposomes formed.  
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Fundamental principle 
Laser diffraction is based on the principle that particles scatter light in all directions 
with an intensity pattern depending on the particle size. A light scattering instrument 
was used consisting of a light beam (usually a laser), a detector to measure the 
scattering pattern, a small volume dispersion unit and a computer for both control of the 
instrument and calculation/computation of the particle size distribution (Chu, 1991). 
Advantages in using this method are that it is easy to use and less time consuming. It is 
reproducible and an extremely wide size range is covered straddling almost five orders 
of magnitude ranging from nanometres to millimetres (Ruf et al., 1989). 
 
Figure 1.15 An illustration of particle size analyser (Adapted from http://www.malvern.com/ 
LabEng/products/Mastersizer/MS2000/mastersizer2000.htm). 
 
1.5 Microparticles 
The most widely used clinical drugs are often found to be of low molecular weight 
exhibiting a short half-life in the blood stream and an overall high clearance rate    
(Haag and Kratz, 2006). Such small molecules diffuse into the healthy tissues in a rapid 
manner and are distributed throughout the body. Based on their size such molecules are 
known as either microparticles or nanoparticles. The advantage of nanoparticles over 
microparticles is different as their size opens the potential for crossing the various 
biological barriers within the body. From a positive viewpoint, especially the potential 
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to cross the blood brain barrier may open new ways for drug delivery into the brain. In 
addition, the nanosize also allows for access into the cell and various cellular 
compartments including the nucleus (De Jong and Borm, 2008). Microparticles on other 
hand also carry these advantages but at certain aspects require surface modification to 
pass through various cellular compartments. 
In order to optimize the biodistribution of drugs to target sites a number of 
nanoparticulate delivery systems for disease targeting and site-selective drug release 
have been developed as described by Dr. Paul Ehrlich over a century ago who described 
the concept of drug delivery at a disease site without harming the healthy tissue as the 
“magic bullet” (Witkop, 1999). Drug delivery systems are classified as either polymer-
drug conjugates (polymer therapeutics) or as nanoparticle therapeutics both approaches 
aim at increasing the therapeutic index maximum quantity of the drug molecules 
available at the target site with reduction of systemic drug exposure. (Davis et al., 2008; 
Caliceti and Veronese, 2003).  
In developing a drug delivery system certain aspects are taken in to consideration as the 
system should positively impact on the rate of metabolism, distribution absorption and 
excretion of the drug or other related chemical substances in the body.  The structure of 
the polymeric nanoparticles enables the drug to bind to its target receptor and influence 
receptor’s signalling and activity (Fig. 1.16). The substance used for the development of 
the microparticles should be degradable into fragments after completion of their role 
and be either metabolised or excreted (Niidome et al., 2006; De Jong and Borm, 2008). 
Thus, for effective and safe drug delivery systems, biodegradable nanoparticle 
formulations are favoured for the purpose transportation and release of the drug in order 
to be effective (Gupta and Gupta, 2005). The use of nanotechnology in drug delivery 
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systems and in medicine is spreading rapidly. Pharmaceutical sciences have been using 
this technology to reduce toxicity and side effects of the drugs. Numerous substances 
have been considered to use for drug delivery systems and more specifically in cancer 
therapy (Ferrari, 2005). 
 
Figure 1.16 Representation of the structure of PLGA nanaoparticle encapsulating a drug 
(Modified from Mamo et al., 2010). 
 
 
1.5.1 Applications of microparticles 
Drug delivery and other pharmaceutical developments related to nanomedicine pose a 
special function related to treatment, prevention and diagnosis of the disease. In order 
for appropriate selection of carriers to be used in drug delivery systems certain 
parameters needs to be considered such as drug incorporation and release, 
biocompatibility and biodistribution, stability and shelf life related to formulation and 
site targeting (De Jong and Borm, 2008). A major issue of limiting intracranial 
therapeutic levels for chemotherapeutic agents’ administration is the blood brain barrier. 
TMZ is one of the most effective anticancer agents to cross the blood brain barrier, 
however, in high systemic doses it is unable to achieve the therapeutic brain levels due 
to its short half-life and also causes certain side effects (Rongy et al., 2005). Thus, 
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according to the literature reports it is proved that implantation of polymeric devices 
have extended the release period of the drug (Zhang and Gao, 2007). 
Drug delivery can be localized or systemic. Parenteral drug delivery is typically 
achieved using liposomal or polymeric carriers (Langer, 1998). There is no universal 
platform, as each system has its advantages and disadvantages. While liposomes have a 
high drug-carrying capacity, their release profiles are more difficult to regulate. In 
contrast, polymeric drug-delivery systems can be synthesized to generate specific 
molecular weights and compositions, but their drug-carrying capacity is relatively low 
(Duncan, 2003). While an ideal general drug-delivery platform may never be realized, 
hybrid drug-delivery systems that incorporate the benefits of various approaches will be 
tailored to address the needs of specific applications. In addition to the standard 
advantages of polymeric and liposomal drug-delivery systems, including sustained and 
controlled release, as well as the potential for targeted delivery, nano-scale dimensions 
confer improved bioavailability by increasing the payload’s solubility and stability. 
Smaller particle sizes facilitate deeper penetration into capillaries and through 
fenestrations and, ultimately, enhanced cellular uptake. Indeed, 100 nm size particles 
exhibit in situ uptake efficiencies 15–250-fold of those of small microparticles (1 and 10 
μm) (Desai et al., 1996). Nanoparticles have even been shown to cross the blood–brain 
barrier. 
1.5.2 Poly(d,l-lactide-co-glycolide) (PLGA) 
In order to meet the requirements of a sustained release system a biodegradable polymer 
such as polylactide (PLA) and its copolymers (PLGA) with glycolide (GA) are 
commonly used. PLGA has proved to be a much more effective polymer than PLA 
because of its polymer properties i.e. manipulation of the co-monomer ratio, molar mass 
and polymer crystallinity (Fig. 1.17). In addition, drug release rates can be controlled 
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through alteration in the ratio, use of different molecular weight PLGA and also in the 
physical characteristics of the resulting microparticles. Degradation of the PLGA plays 
a crucial role in the drug release mechanism (Porjazoska et al., 2004). Furthermore, 
previous studies have reported the biocompatibility and biodegradability of blank PLGA 
(i.e. without any active ingredient encapsulated in it) in brain cells when implanted in 
brain tissue (Emerich et al., 1999; Menei et al., 1993). The blood brain barrier consists 
of tight junctions of blood vessels of brain endothelial cells, thus the application of 
prodrugs and drug carriers have been used to overcome this limitation. The surface 
modified carriers have drawn the attention due to their ability for site specific delivery 
of the drug (Zhang and Gao, 2007). Because of their small size and modified surface 
these polymeric nanoparticles can also be targeted to specific cells and locations in the 
body. The factors such as drug encapsulation and release profile depend on the type of 
polymer used and its physiochemical characteristics such as particle size and 
morphology (Torchilin, 2006a).  The melting point of PLGA is found to be amorphous 
and the glass transition temperature is reported to be 45-50 °C.  
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Figure 1.17 Representation of the structure of PLGA (The chemical structure was drawn using 
the chemdraw ultra 12.0 software). 
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1.5.3 Techniques used in the current study for formation of Microparticles 
The preparation of the PLGA microparticles involved both emulsifying-solvent 
evaporation and spray dry techniques. The emulsifying-solvent evaporation consists of 
dissolving the polymer with the drug in a solvent and mixing it with aqueous medium 
containing surfactant. The mixture stirred overnight during which time diffusion takes 
place between the water-soluble solvent and the water-insoluble phase, resulting in an 
interfacial turbulence which results in the formation of microparticles (Torchilin, 
2006b). Spray dry technique is performed by using a Mini Spray Dryer. Polymer 
together with the drug was dissolved in a solvent which is subjected to spray drying 
where the matrix material and the active ingredients are heated above the melting point 
(Wang and Wang, 2003). The microparticles are formed based on the principle of a     
co-current air and product stream, i.e. the sprayed product and hot air have the same 
flow direction (Fig. 1.18). Compressed air is used for the dispersion of the liquid body 
into fine droplets which are subsequently dried in the cylinder. These droplets are 
solidified into particles and can thus be separated.  
 
 
Figure 1.18 Functional principle of the spray dry method. (Adapted from http://www.mybuchi. 
com/Mini_Spray_Dryer_B-290.179.0.html). 
 
48 
 
The spray drying technique converts the drug–polymer suspension into fine particles by 
spraying through an atomization nozzle into hot air. The solvent present within the 
atomized droplets evaporates quickly and solid microparticles are formed. This 
technique has been used previously to encapsulate anticancer drugs such as paclitaxel 
and etanidazole respectively into PLGA microparticles (Mu and Feng, 2001;          
Wang and Wang, 2003). 
1.5.4 Dissolution techniques used for determination of drug release from the 
microparticles. 
Two dissolution techniques used to monitor the release of drugs from liposomes and 
microparticles are dispersion and dialysis bag diffusion methods. The release process of 
drugs from microparticles is based on the physiochemical characteristics of the drug 
molecules and the matrix of the polymer (Hutchison and Furr, 1990). Certain aspects in 
which the release of the drug depends include the mode of drug attachment or 
encapsulation involving factors such as surface adsorption, covalent conjugation and 
dispersion homogeneity of the drug molecules in the polymer matrix, in addition to this 
the factors determining the degradation and the control of matrix hydration are also 
involved (Allemann et al., 1993; Niwa et al., 1993; Soppimath et al., 2001).  
The release of the drug from the polymer can be described in different phases, rapid 
release of the drug occurs due to desorption this can be due to the drug being bonded 
weakly to the polymer surface and can be expressed as the initial burst release phase 
which can sometimes takes place as result of bulk degradation of the polymer 
(Allemann et al., 1993; Polakovic et al., 1999; Panyam et al., 2004; Liu et al., 2005; 
Tamber et al., 2005). If the bulk degradation of the polymer is made to exhibit surface 
degradation or layer-by-layer degradation, the polymer could present a promising 
control release of the drug. These phenomena is termed as sustained release (Conte et 
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al., 1993; Abdul and Poddar, 2004; Chen et al., 2005; Loo et al., 2005;                    
Frank et al., 2005; Loo et al., 2010). If the drug is distributed uniformly in the matrix of 
the polymer, the release takes place by diffusion (i.e. if the drug is in a crystalline form 
it is first dissolved locally and then diffusion takes place). Sometimes the release takes 
place by the erosion of the matrix or a combination of both mechanisms causes the 
release (Torchilin, 2006a). The stage where no drug release is observed is termed as the 
lag phase, where the drug is not diffusing out of the polymer, one of the mode by which 
this could be overcome by treating the sample by radiation (e-beam) which modifies the 
physical properties of the polymer and thereby reduces the lag phase (Miao et al., 2009; 
Loo et al., 2010). Some of the parameters that should be taken into consideration for 
monitoring the release mechanism include polymer molecular weight distribution, 
melting and glass transition temperature, crystallinity and hydrophobicity or 
hydrophilicity. It is also observed from previous studies that degradation time of the 
polymer is shorter for low molecular weight polymers and greater for amorphous, 
hydrophilic and polymers with high glycolide content (Gallia et al., 2005; Torchilin, 
2006a). 
1.5.5 Particle size analysis  
The scanning electron microscope (SEM) was used for analysing the particle size and 
morphology of the TMZ and Patrin-2 loaded PLGA microparticles. In order to generate 
a range of signals at the surface of the microparticles SEM uses a focussed beam of high 
energy electrons (Fig. 1.19). The signals generated is attributed to electron and sample 
interactions and provides details on the sample related to its external morphology, size, 
chemical composition and orientation of materials used in making of the sample 
(Painbeni et al., 1998). Data is collected from the selected surface area of the sample 
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and a two dimensional image is produced displaying the spatial differences in these 
properties.  
 
Figure 1.19 Schematic diagram of scanning electron microscopy. (Adapted from http://cms. 
daegu.ac.kr/sgpark/microbiology/SEM.jpg). 
 
Fundamental principle 
The signals generated by electron-sample interactions include secondary electron (that 
are responsible for producing the SEM image), backscattered electrons, diffracted 
backscattered electrons (used in determination of the crystalline structure of the 
sample), photons, visible light and heat. The essential components of SEM includes the 
electron source, electron lenses, sample stage (where the sample is placed for analysis), 
detectors for analysing all possible signals, and the display or data output device 
(Bodmeier et al., 1989). 
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1.6 High Performance Liquid Chromatography (HPLC) 
All quantitative analysis of the actives encapsulated in both liposomes and 
microparticles were performed using HPLC. HPLC is a form of column 
chromatography used frequently in pharmaceutical analysis to separate, identify and 
quantify various compounds (Lindsay and Barnes, 1992).  Though there are two modes 
one being isocratic and the other gradient the separation of the compounds, in this study 
was carried out using isocratic mode in which the mobile phase composition remains 
constant throughout the procedure. The HPLC system consists of a stationary phase 
(column), mobile phase, injector, pump and a detector (Fig. 1.20).   
Most widely two type of HPLC are used that are normal and reverse phase 
chromatography. These two types can be distinguished on the basis of relative polarities 
of the mobile and stationary phase (Lindsay and Barnes, 1992). Normal phase 
chromatography consists of highly polar stationary phase such as water or triethylene 
glycol and the mobile phase is a relatively non-polar solvent such as hexane or i-propyl 
ether while the reverse phase chromatography consists of the typical stationary phase 
which are non-polar hydrocarbons, waxy liquids or bonded hydrocarbons such as C18, 
C8 or C4 while its mobile phase is a relatively polar solvent such as methanol, water, 
acetonitrile, or tetrahydrofuran (Skoog and Leary, 1992). The C18, C8 and the phenyl 
bonded phases are most often used in the reverse phase mode (Skoog et al., 2007). 
Bonded phases are made by bonding of a molecule covalently on to a solid stationary 
phase which is intended to prepare liquid coatings which will be permanent             
(Skoog and Leary, 1992). Silica is a reactive substrate used, to which the functionalities 
such as the alkyl (C18 and C8), cyano, aromatic phenyl and amino groups can be 
attached or bonded. In normal phase, the least polar component is eluted first thereby 
increasing the polarity of the mobile phase and decreasing the elution time (Skoog and 
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Leary, 1992). However, in reverse phase chromatography the most polar component is 
eluted first, increasing the polarity of the mobile phase and increasing the elution time 
(Lindsay and Barnes, 1992). One of the many advantages of reverse phase 
chromatography is the ability to use water as the mobile phase which is an inexpensive 
and UV-transparent solvent compatible with biological solutes, also it is found that 
mass transfer as well as solvent equilibration is rapid with non-polar stationary phase 
(Skoog et al., 2007). The R group of the siloxane used in these coatings is a C18 chain 
(n-octyldecyl) or C8 chain (n-octyl). The effect of the alkyl groups on performance 
depends on the chain length (Skoog and Leary, 1992). Longer chains produce packings 
that are more retentive and allow use of larger samples, the maximum sample size of 
column type C18 is roughly twice of that of C4 under similar conditions (Skoog et al., 
2007). 
The technique involves separation of the components in a mixture pushed through the 
column usually at a constant flow rate is carried out using a liquid mobile phase. The 
solvent (mobile phase) is run through the high pressure pump which generates and 
measures the flow rate of the mobile phase in millilitres per minute. The sample to be 
analysed is introduced in the injector from where it is introduced in the mobile phase 
flowing through the column consisting of chromatographic packing material (C18) also 
termed as the stationary phase. From the column the flow is directed to the detector. The 
components are then analyzed by the detector from where the chromatographic image is 
produced in the computer. The detector normally used is a UV lamp. The chromatogram 
produced displays the retention time and the peak area of the expected compound. The 
retention time is a characteristic of the sample for a particular set of conditions and 
helps in identification of the compound. The peak area of the compound indicates the 
concentration of the compound used in the analysis (Lindsay and Barnes, 1992). 
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Figure 1.20 Schematic diagram of HPLC (Adapted from http://www.waters.com/waters/ 
nav.htm?cid=10049055&locale=en_GB). 
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1.7 The main research questions & aims  
Questions to be addressed concerning the investigation  
Can the preparations of liposomes and microparticles be effectively used for 
encapsulation of TMZ and Patrin-2? 
Can their release from the formed liposomes and microparticles be efficiently monitored 
using the dissolution techniques in order to enhance the treatment of glioma? 
Hypothesis 
TMZ & Patrin-2 could be encapsulated separately into liposomes and microparticles 
using established or improvised methods. 
1.7.1 Main aim 
The main aim of our investigation was to prepare TMZ loaded liposomes (by using 
different ratios of phospholipid), TMZ loaded PLGA microparticles and Patrin-2 loaded 
PLGA microparticles.  
TMZ has proved to be effective in patients that lack MGMT activity since MGMT 
counteracts the effect of TMZ by removing the methyl group (originally added by 
TMZ) (Rimel et al., 2009). Patrin-2 is used to counteract the effect of MGMT and 
enhances the effective activity of TMZ. Because TMZ and Patrin-2 are not compatible 
due to their differences in stability at different pH’s they cannot be encapsulated 
together in the same vehicle, thus the microparticles formulations prepared for both 
drugs were prepared separately. 
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1.7.2 Specific aims of the research:  
1. To establish a method for the preparation of TMZ loaded liposomes with 
maximum encapsulation efficiency monitored by HPLC and to determine 
particle size. 
2. To establish a method for preparing TMZ loaded microparticles resulting in 
maximum encapsulation monitored by HPLC. 
3. To use different molecular weights of PLGA for the preparation of TMZ and 
Patrin-2 loaded microparticles.  
4. To measure the particle size and morphology of the TMZ and Patrin-2 loaded 
microparticles using scanning electron microscopy. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Materials 
Materials used in this study are detailed in Table 2.1. All chemical reagents used were 
of analytical grade. All materials used were handled and stored according to the 
instructions given by the suppliers. 
Table 2.1 Materials used in this study. 
Chemicals Molecular weight 
(Da) 
Supplier  
TMZ  
 
194.15 Sigma Aldrich (UK) and 
Paterson institute (UK) 
Patrin-2 (Lomeguatrib) 326.17 Zhejiang Wonderful Pharma 
& Chem Co. (China) 
Lα-phosphatidylcholine  760.09 Sigma Aldrich (UK) 
1,2-distearoyl-sn-glycerol-3-
phosphocholine  
677.93 Sigma Aldrich (UK) 
1,2-dimyristoyl-sn-glycerol-3-
phosphocholine  
734.10 Sigma Aldrich (UK) 
Lipoid S-100 Lecithin from soy  790.00 Lipoid GmbH (Germany) 
Stearic acid  284.48 Sigma Aldrich (UK) 
Cholesterol 386.67 Sigma Aldrich (UK) 
Phospholipon
®
 90H  784.00 Phospholipid GmbH 
(Cologne) 
Poly (DL-lactide-co-glycolide) 
(75: 25)  
1.7x10
4
 Purac biomaterials 
(Netherlands) 
Poly (DL-lactide-co-glycolide) 
(75: 25)  
6.6x10
4
 - 1x10
4
 Sigma Aldrich (UK) 
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Poly (DL-lactide-co-glycolide) 
(50: 50)  
4x10
4
 – 7.5x104 Sigma Aldrich (UK) 
Poly (DL-lactide-co-glycolide) 
(50: 50)  
1.5 x10
4
- 4 x10
4
 Sigma Aldrich (UK) 
Dialysis tubing, benzolated  MW cut off 1200-
2000  
Sigma Aldrich (UK) 
Polyvinyl alcohol 20000 - 30000 Fisher Scientific (UK) 
Sodium Dodecyl Sulphate (SDS) 288.38 Sigma Aldrich (UK) 
Citric acid 192.12 Sigma Aldrich (UK) 
Tetrabutylammonium acetate 
(TBAA) 
301.51 Sigma Aldrich (UK) 
Phosphate buffered saline (PBS 
1x) 
N/A Autogen Bioclear (UK) 
HPLC grade chloroform N/A Fisher Scientific (UK) 
HPLC grade dichloromethane N/A Fisher Scientific (UK) 
HPLC grade acetonitrile N/A Fisher Scientific (UK) 
HPLC grade acetone N/A Fisher Scientific (UK) 
HPLC grade ethanol N/A Fisher Scientific (UK) 
HPLC grade methanol N/A Fisher Scientific (UK) 
HPLC grade water   N/A Fisher Scientific (UK) 
Acetic Acid N/A Fisher Scientific (UK) 
Triton X-100 N/A VWR International (UK) 
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2.2. Equipments 
All the instruments used to carry out the experiments are detailed in table 2.2. 
Table 2.2 Equipment used in this study  
Equipment Type Supplier 
HPLC pump Jasco PU-1580 Jasco (UK) 
HPLC detector Jasco UV-970M  
(4-λ intelligent) 
Jasco (UK) 
HPLC Column Shandon C18 Thermo scientific (UK) 
Mini spray dryer Buchi mini spray dryer B-290 Buchi (UK) 
Particle size analyser Mastersizer 2000 Malvern instruments ltd. 
(UK) 
Scanning electron 
microscopy (SEM) 
Scanning electron microscopy Edax-ametex (UK) 
Water bath  Nuve water bath nb 5 Biotech lab (Bulgaria) 
Centrifuge Centrikon T-324 Kontrons instruments 
(UK) 
Rotary evaporator Buchi RE111 and Buchi 461 
water bath 
Buchi (UK) 
Gold coater Sputter coater Emitech ltd. (UK) 
Shaker and incubator  Shaker and incubator Gallenkamp (UK) 
Microcentrifuge Microcentrifuge MSE Sanyo (UK) 
Tube rotator Blood tube rotator SBI Jencons scientific (UK) 
Magnetic stirrer RCT basic IKA RCT basic 
(Germany) 
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Sonicator Ultra sonicator- ULT065 Ultra wave (UK) 
Analytical Balance Balance P/PI-114 Denver instruments 
(UK) 
Micropipettes Gilson Thermo Scientific (UK) 
Vortex  Whirl mixer Fisons scientific 
equipment (UK) 
 
2.3 HPLC methods 
2.3.1 HPLC instrumentation 
HPLC system used in the study consisted of Jasco PU-1580 pump attached to a Jasco 
UV-970M (4-λ intelligent) and a Viglen Pentium-4 contender with an AZUR version 
5.0.10.0 software package for analysis of TMZ and Patrin-2 (Fig. 2.1).  
 
Figure 2.1 High Performance Liquid Chromatography coupled with UV detector used for 
sample analysis. 
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2.3.2 HPLC column 
The chromatography was performed using a Shandon C18 (150 × 4.60 mm) column 
consisting of particle sizes equivalent to 5 µm. Manual injections were carried out using 
a Rheodyne model 7725i injector with a 20 µl loop. The mobile phase used for TMZ 
was 0.5 % acetic acid:methanol in the ratio of 9:1 (pH 2.8) (Moffat et al., 2004) and the 
mobile phase used for Patrin-2 was 35 % acetonitrile consisting of 10 mM 
tetrabutylammonium acetate (TBAA), 10 mM sodium dodecyl sulphate (SDS) and 
25 mM citric acid (pH 3.4) (Shervington et al., 2005). Analysis was performed only 
after the column had reached equilibrium (approximately 30-60 min at a flow rate of      
1 ml/min). The mobile phase was always filtered and degassed before use. The final 
flow rate was set to 1 ml/min and the detector was set to monitor at wavelengths 330 nm 
and 287 nm. All the analyses were carried out at ambient temperature (25 
o
C).  
2.3.3 Validation of HPLC system 
The validation of HPLC system for TMZ and Patrin-2 was carried out following 
standard procedures described in United States Pharmacopoeia (USP). This included 
linearity, repeatability and reproducibility, limit of detection and limit of quantification.  
2.3.3.1 Selection of Mobile phase: 
Based on the literature review the following two mobile phases were used for TMZ and 
Patrin-2.  
1) For the analysis of TMZ: 0.5% acetic acid:methanol in the ratio of 9:1(v/v). 
This mobile phase was prepared by mixing 100 ml of methanol to 900 ml of 0.5 % 
acetic acid. It was then sonicated and filtered before running it on the HPLC system. 
The pH of the mobile phase was found to be 2.8 (Moffat et al., 2004).  
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2) For the analysis Patrin-2: 35 % acetonitrile consisting of 10 mM TBAA, 10 mM SDS 
and 25 mM citric acid was used. 
This mobile phase was prepared by mixing 175 ml of HPLC grade acetonitrile with 325 
ml of HPLC grade water to which 1.5076 g of TBAA, 1.4419 g of SDS and 2.4015 g of 
citric acid was added and dissolved. It was then sonicated and filtered before running it 
on the HPLC system. The mobile phase pH was measured to be 3.4              
(Shervington et al., 2005). 
2.3.3.2 Stock solution: 
Stock solution for TMZ was prepared by adding 10 mg of the TMZ to a 100 ml 
volumetric flask dissolving it with mobile phase and then making up to the mark with 
the mobile phase, thus giving a final concentration of 0.1 mg/ml. Similarly, 10 mg of 
Patrin-2 was added to a 100 ml volumetric flask dissolving it with acetonitrile and 
making up to the mark with acetonitrile to give a final concentration of 0.1 mg/ml. The 
stock solutions were stored in a refrigerator at 4 °C.  
2.3.3.3 Calibration curve (linearity testing of the HPLC system): 
For linearity testing of TMZ and Patrin-2, aliquots of concentration 0.08, 0.06, 0.04, 
0.02 and 0.01 mg/ml were prepared from stock solutions and the corresponding peak 
areas were determined and the calibration curves were plotted.    
2.3.3.4 Repeatability (Intraday analysis): 
Intraday analysis was carried out for TMZ and Patrin-2 by analysing the sample at a 
concentration of 0.02 mg/ml six times on the same day and the SD and RSD were 
determined. 
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2.3.3.5 Reproducibility: 
Reproducibility for TMZ and Patrin-2 were carried out by analysing six samples of both 
TMZ and Patrin-2 at a concentration of 0.02 mg/ml individually on the same day. Each 
sample was analysed twice and the SD and RSD were determined. 
2.3.3.6 Limit of detection (LOD) and Limit of quantification (LOQ): 
The limit of detection (LOD) is the minimum concentration at which an analyte can be 
detected. LOD for TMZ and Patrin-2 was carried out by diluting the samples from an 
initial concentration of 0.01 mg/ml and gradually decreasing the concentration down to 
a point where the detector was just able to distinguish between the signals to noise ratio. 
Based on the limit of detection of TMZ and Patrin-2, the limit of quantification was 
carried out by determining the lowest quantifiable concentration that could be achieved 
in a repeated manner with an acceptable RSD. 
2.4 Stability test of TMZ and Patrin-2: 
In order to determine whether TMZ and Patrin-2 were compatible in PBS at a pH of 7.4 
following tests were carried out.  
2.4.1 Standard solution: 
Standard solution for TMZ was prepared by dissolving 5 mg of the TMZ into a 100 ml 
volumetric flask and then making up to the mark with the mobile phase, thus giving a 
final concentration of 0.05 mg/ml. Similarly, two different solutions were prepared one 
consisting of 5 mg of Patrin-2 and other consisting of a combination of 5 mg of each 
TMZ and 5 mg of Patrin-2 dissolved in acetonitrile in a 100 ml volumetric flask, thus 
providing a final concentration of 0.05 mg/ml for each. All the stock solutions were 
stored in a refrigerator at 4 °C.  
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2.4.2 Compatibility test of the two drugs TMZ and Patrin-2: 
TMZ, Patrin-2 and a combination of TMZ and Patrin-2 stock solutions were prepared at 
a concentration of 0.05 mg/ml in mixture of PBS and ethanol (ratio of 8:2). The three 
solutions were stored at: 25, 37 and 50 °C. The samples were analysed after every         
3 days. In addition to these samples a dry sample reaction was carried out, a vial 
consisting of 10 mg of TMZ and 10 mg of Patrin-2 were mixed and subjected to stress 
condition at 50 °C for 1 week. Both the compounds were then solubilised in a mixture 
of PBS and ethanol (ratio of 8:2) at concentrations of 0.05 mg/ml because Patrin-2 is not 
soluble in PBS alone ethanol was introduced to dissolve Patrin-2 in the solution 
maintaining the pH at 7.4. 
2.5 To develop liposomal preparation of TMZ: 
2.5.1 Freeze–Thaw method: 
Liposomal formulation of TMZ was carried out by combining 10 mg of TMZ with 
phospholipids in ratios 1:1, 1:2 and 1:3 (calculated in moles) and the phospholipid 
providing the better entrapment was further combined with cholesterol in ratios 1:1:1, 
1:2:1, 1:2:2, 1:3:1 and 1:3:2 (calculated in moles). To this mixture 2 ml of phosphate 
buffered saline (PBS) of pH 7.01 was added and then placed on the rotor set at 34 rpm 
for 30 min. The dispersion was vortexed intermittently for 30 min, this step was 
performed in six cycles i.e. 2 min vortexing, 3 min interval in a water bath kept at 65 
°C. After vortexing the dispersion, the mixture was immersed in liquid nitrogen for 3 
min and then immediately transferred to a water bath kept at 65 °C for 6 min (the 
freeze–thaw cycle was repeated six times) (Shazly et al.,  2008). The entrapment of the 
drug was aided by the freezing process, while the thawing process was used to rupture 
multilamellar vesicles in order to help the incorporation of the enclosed contents with 
the release medium. After completion of the freeze-thaw cycles, the liposomal 
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dispersion was allowed to stand for 1 hr to maximise further encapsulation of the drug 
(Mohammed et al., 2004). The determination of the encapsulation efficiency (EE %) 
was carried out as described in section 2.5.3. 
[Phospholipid: lα-phosphatidylcholine, DMPC, DSPC, phospholipon 90H and lecithin]  
2.5.2 Dehydration-Rehydration method: 
Similar to thin film method: Liposomal formulation of TMZ was carried out by 
combining 10 mg of TMZ with phospholipids in ratios 1:1, 1:2 and 1:3 (calculated in 
moles) and the phospholipids providing the best entrapment was further combined with 
cholesterol/stearic acid in ratios 1:1:1, 1:2:1, 1:2:2, 1:3:1 and 1:3:2 (calculated in 
moles). To this mixture 2 ml of methanol and 10 ml of chloroform was added and then 
transferred to a 50 ml round bottom flask. The flask containing the mixture was placed 
on a rotary evaporator set at 65 °C for 4 hr to produce a thin film of the mixture. The 
thin film was flashed with  nitrogen gas for 15 min at approx. 4 psi in order to help 
eliminate traces of the solvent in the film. The thin film was rehydrated with 2 ml of 
PBS and the suspension was vortexed for 4 min (along with hand shaking the flask and 
keeping it in the water bath at 40 °C) to form liposome (Glavas-Dodov et al., 2005). 
After vortexing of the suspension, it was allowed to stand at room temperature for 1 hr 
for further encapsulation of the drug to form liposome.  
[Phospholipid: lα-phosphatidylcholine, DMPC, DSPC, phospholipon 90H and lecithin] 
2.5.3 Determination of EE %: 
The EE is the actual weight of the drug entrapped in the liposome compared to the 
initial amount of drug weighed out. The determination of EE % of TMZ for          
freeze-thaw and dehydration-rehydration method was carried out as described below. 
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Before sample (ADb):   After 1 hr of incubation of the liposomal dispersion at 25 °C, 
100 µl  was taken and mixed with 2 ml of triton X-100 (10 %) and 7.90 ml HPLC grade 
water to make it up to a final volume of 10 ml. The solution was maintained in a water 
bath for 5 min at 65 °C and vortexed for 2 min and then analysed by HPLC     
(Maestrelli et al., 2006). 
After sample (ADa): The remaining liposome suspension was washed twice with PBS        
(10 ml) and centrifuged for 30 min at 10000 g at a temperature of 4 °C. The pellet 
obtained from the centrifugation was mixed with 2 ml of PBS. From the liposome 
suspension 100 µl was removed and mixed with 2 ml of triton X-100 (10 %) and       
7.90 ml HPLC grade water to produce a final volume of 10 ml. The solution was 
maintained in a water bath at 65 °C for 5 min and vortexed for 2 min and then analysed 
by HPLC (Kawano et al., 2003). 
The EE % was determined by the following equation (Shazly et al., 2008): 
EE %=ADa x 100 
ADb 
 
Where ADb and ADa are peak area obtained for TMZ in liposome before and after 
washing with PBS, respectively. 
2.6. Methods used for preparation of PLGA microparticles were emulsifying-
solvent evaporation method and spray dry method: 
2.6.1. Emulsifying-solvent evaporation method: 
Solution A: 200 mg of PLGA was dissolved in 10 ml of HPLC grade dichloromethane 
to which 5 mg of TMZ was added and sonicated for 10 min.  
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Solution B: Polyvinyl alcohol (PVA) (2 %) solution was prepared by dissolving 2 g of 
PVA in 100 ml of HPLC grade water continuously stirring the solution at 50 °C for 
about 45 min.  
80 ml of a volume of PVA (2 %) was kept at room temperature continuously stirred at 
600 rpm using magnetic stirrer to which solution A was added. The emulsion was kept 
continuously stirring at 600 rpm overnight in order to evaporate dichloromethane from 
the solution. Once the organic solvent was completely removed, the suspension was 
washed with HPLC grade water and the recovered microparticles were filtered using   
0.7 µm glass fibre filter paper fitted in to a grade 3 glass sinter. The microparticles were 
stored overnight in a desiccator in order to remove any residue of water from the 
collected powder (Zhang and Gao, 2007). The microparticles were solubilised in 10 ml 
of dichloromethane using a sonicator and 30 ml of methanol was added to the solution 
in order to precipitate PLGA. The suspension was centrifuged for 30 min at 10000 g and 
the supernatant was analysed by HPLC.  
2.6.2 Determination of EE % of the TMZ loaded PLGA microparticles: 
The EE is the actual weight of the drug entrapped in the polymeric carrier compared to 
the initial amount of drug weighed out. The drug content in the supernatant was then 
checked using HPLC. 
The EE was determined from the following equation (Seong et al., 2003): 
EE %= Dm × 100 
Dt 
 
Where Dt is the peak area obtained from the standard solution of TMZ and Dm is the 
peak area obtained for TMZ in the microparticles. 
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Each preparation also involved the preparation of a standard solution (Dt) along with the 
reaction mixture in order to measure the amount of drug encapsulated. The standard 
solution was prepared by adding 5 mg of TMZ to a 40 ml volumetric flask dissolving it 
with mobile phase (0.5 % acetic acid and methanol in the ratio 9:1) and making up to 
the mark with the mobile phase. Analysis of the solution was carried out using HPLC. 
Alternative method of calculation which can be used: 
The EE was determined from the following equation (Seong et al., 2003): 
EE %= Dm × 100 
Dt 
 
Where Dt is the amount of TMZ theoretically present in the microparticles collected (in 
weight) and Dm is the peak area obtained for TMZ in the microparticles. 
 
2.6.3 Spray dry method: 
2.6.3.1 The preparation of TMZ loaded PLGA microparticles and Patrin-2 loaded 
PLGA microparticles: 
A sample of 100 mg of PLGA and 5 mg of TMZ were dissolved in 30 ml of acetone. 
The solution was then spray dried using a mini spray dryer (Fig. 2.2). The aspirator was 
set at 100 % and inlet temperature was set at 60 °C (10 °C higher than the boiling point 
of acetone). The nitrogen q-flow was set at 30 mbar and the pump speed was adjusted to 
20 %. The microparticles formed through spray drying were collected from the 
collection vessel and the cyclone by washing with acetone. The acetone was evaporated 
and the microparticle weighed out was approximately 32 mg. The microparticles were 
again washed with 30 ml of water in order to remove any unencapsulated drug. The 
suspension was centrifuged for 30 min at 20000 g with the temperature set at 4 °C and 
the supernatant was analysed using HPLC. The pellet obtained was treated with 4 ml of 
69 
 
acetone to dissolve the microparticles followed by 25 ml of methanol to precipitate 
PLGA. The suspension was centrifuged for 30 min at 10000 g with the temperature set 
at 4 °C and supernatant was analysed using HPLC (Seong et al., 2003).  
 
Figure 2.2 Mini Spray Dryer used for preparing the microparticles. 
 
Patrin-2 loaded PLGA microparticles was prepared using the same protocol as 
described in section 2.5.3.1 except the amount of microparticle collected and weighed 
out was approximately 36 mg and that ethanol was used instead of water for washing 
the microparticles. 
2.6.3.2 Determination of EE % of TMZ and Patrin-2 loaded PLGA microparticles: 
The EE % of TMZ and Patrin-2 was determined from the following equation         
(Seong et al., 2003): 
70 
 
EE %= Dm × 100 
Dt 
 
Where Dt is the peak area obtained from the standard solution of TMZ and Dm is the 
peak area obtained for TMZ in the microparticles. 
Each preparation also involved the preparation of a standard solution (Dt) along with the 
reaction mixture in order to measure the amount of drug encapsulated. The standard 
solution was prepared by adding 5 mg of TMZ to a 30 ml volumetric flask dissolving it 
with mobile phase (0.5 % acetic acid and methanol in the ratio 9:1) and making up to 
the mark with the mobile phase. Similarly, standard solution for Patrin-2 was prepared 
by adding 5 mg of Patrin-2 to a 30 ml of volumetric flask dissolving it with acetonitrile 
and making up to the mark with acetonitrile. Analysis of the solutions was carried out 
using HPLC.  
Alternative method of calculation which can be used: 
The EE was determined from the following equation (Seong et al., 2003): 
EE %= Dm × 100 
Dt 
 
Where Dt is the amount of TMZ theoretically present in the microparticles collected (in 
weight) and Dm is the peak area obtained for TMZ in the microparticles. 
2.7 Particle size analysis of liposome and microparticles: 
2.7.1 Particle size analysis of liposome using the mastersizer. 
Liposome prepared by using freeze-thaw and dehydration-rehydration method were 
analysed using the mastersizer (Fig. 2.3). Particle size distribution was plotted using a 
computer program Mastersizer 2000 software version 5.20 which was supplied by the 
manufacturer. The system was first cleaned with distilled water; the small volume 
dispersion unit was filled with 100 ml of distilled water to which 200 µl of the sample 
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was added to reach the laser obscuration up to 12-13 % in order to obtain the particle 
size.  
 
  Figure 2.3 Mastersizer 2000 used for particle size analysis. 
 
2.7.2 Particle size analysis of microparticles using the scanning electron 
microscopy (SEM). 
The particle size and morphology was carried using a technique called scanning electron 
microscopy (Fig. 2.4). The technique was applied for measuring microparticles prepared 
by emulsifying-solvent evaporation and the spray drying method. Approximately 2 mg 
of the microparticles was spread evenly on an aluminium stub which was plated with 
gold at 50 milliamps and then placed in the chamber of the SEM for analysis. Images of 
the particles were obtained using a computer program Quanta-XTM 200 version 2.01 
supplied by the FEI Company, UK. 
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Figure 2.4 Scanning electron microscopy (SEM) used for Particle size analysis.  
 
2.8. Dissolution techniques: 
2.8.1. Dispersion method used for determination of release of TMZ and Patrin-2 
from the microparticles: 
In a screw-capped glass vial (30 ml) containing 25 ml of PBS at pH 7.4, 25 mg of 
microparticles were dispersed by shaking at 200 rpm in an incubator maintained at                
37 ± 0.5 °C (Shazly et al., 2008). At predetermined time intervals (0.5, 1, 2, 4, 6, 12, 24, 
48,72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312 and 336 hr) an aliquot of 1 ml of 
the dispersion was withdrawn and replaced with 1 ml of PBS. The aliquot was 
centrifuged for 30 min at 13,000 g, and the supernatant was analysed using HPLC 
(Burgess et al., 2002). The calculations were carried out using the amount of released 
compound obtained by HPLC analysis and by using the regression equation obtained 
from the calibration curve of both the compounds.  
73 
 
2.8.2. Dialysis bag method used for determination of release of TMZ and Patrin-2 
from the microparticles: 
During the preparation of the dialysis chamber, a 5 ml plastic tube was used with its 
centre of the cap removed with a heated pasteur pipette (wide end). The reaction 
mixture consisted of 25 mg of the microparticles to be dialyzed in a tube with 2.5 ml 
PBS at pH 7.4. A piece of dialysis membrane was placed loosely over top of tube. The 
cap of the tube was gently positioned on the tube and the tube was inverted (Fig. 2.4). 
The sample was placed down onto the dialysis membrane and the tube was attached to a 
50 ml beaker containing 25 ml PBS. The procedure ensured that no bubbles were 
trapped under the membrane (Craig, 1967). The beaker was placed onto a magnetic 
stirrer set at 37 ± 0.5 °C and a magnetic flea was set to rotate at 200 rpm in order to 
encourage agitation. A control was set up along with the reaction mixture in order to 
make a comparison the release of the compound. At predetermined time intervals (0.5, 
1, 2, 4, 6, 12, 24, 48,72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312 and 336 hr) an 
aliquot of 1 ml of the dispersion was withdrawn and replaced with 1 ml of PBS. The 
samples were analysed by HPLC (Burgess et al., 2002). The calculations were carried 
out using the amount of released compound obtained by HPLC analysis and by using 
the regression equation obtained from the calibration curve of both the compounds. 
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Figure 2.5 Preparation of the dialysis chamber to set the reaction (Craig, 1967). 
2.9 Statistical analysis 
For all the methods used for preparation of liposome and microparticles, the 
experiments were performed in triplicate, and the results were expressed as the mean 
±Standard Deviation (SD) from the three or four independent experiments. A statistical 
analysis was performed using SPSS version 18.0.3 and Microsoft Excel. All data for 
freeze-thaw and dehydration-rehydration method were evaluated for ratio variables to 
compare a random sample from a normally distributed samples by one-sample “t-test”, 
P values<0.005(*) and  0.001(**) are considered to be statistically significant. All the 
data for the Spray-dry method was evaluated for unpaired variables to compare two or 
more groups included pairs of the standard with the different molecular weight of 
polymer was tested by paired Student “t-test”, P values<0.005(*) and 0.001(**) are 
considered to be statistically significant.  
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3.1 HPLC methods for TMZ and Patrin-2 analysis. 
Good peak symmetry for TMZ and Patrin-2 were achieved using the mobile phase 
consisting of 0.5 % acetic acid:methanol in the ratio of 9:1(v/v), (pH 2.8) and 35 % 
acetonitrile consisting of 10 mM TBAA, 10 mM SDS and 25 mM citric acid, (pH 3.4), 
respectively. TMZ was analysed at 330 nm while Patrin-2 was analysed at 287 nm. The 
retention time (RT) for TMZ was found to be 3.7 while for Patrin-2 was found to be 5.6 
min, respectively. 
Validation of the HPLC method 
The parameters used for the validation included linearity, repeatability, reproducibility, 
limit of detection (LOD) and limit of quantification (LOQ) for the analysis of both TMZ 
and Patrin-2 are summarised (Table 3.6). 
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3.1.1 Linearity testing 
Linearity for TMZ and Patrin-2 were carried out in the range of 0.01-0.1 mg/ml (Table 
3.1). The calibration curve for TMZ and Patrin-2 were both linear with regression 
coefficients, R
2
 values equal to 0.999 and 0.989, respectively (Fig. 3.1). 
Table 3.1 Linearity testing of TMZ and Patrin-2. Data values are the average of n = 3. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                MPA- Mean Peak Area. 
 
 
 
 
 
 
 
 
 
 
Concentration 
(mg/ml) 
 
TMZ  
MPA 
 
 
Patrin-2 
MPA 
 
 
0.1 
 
5906.59 
 
 
 
3122.22 
 
0.08 
 
4697.39 
  
2745.64 
 
0.06 
 
3549.57 
  
       1750.64 
 
0.04 
 
2369.00 
 
1109.55 
 
0.02 
 
1201.12 
 
531.87 
 
0.01 
 
627.07 
 
 
253.42 
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The mean peak areas obtained from the solution of concentration ranging from             
0.01-0.1 mg/ml for the linearity test were used to plot the calibration curve from which 
the regression coefficient was acquired (Fig. 3.1).  
 (a) 
 
(b) 
 
Figure 3.1 Calibration curve for TMZ and Patrin-2. (a) Calibration Curve for TMZ at 
concentration ranging from 0.01-0.1 mg/ml. (b) Calibration Curve for Patrin-2 at concentration 
ranging from 0.01-0.1 mg/ml. Y denotes dependent variable and x is the independent variable 
while R
2
 is the regression coefficient.  
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3.1.2 Repeatability 
Repeatability of the analytical method was carried out for TMZ and Patrin-2 using a 
concentration of 0.02 mg/ml (Table 3.2). The standard deviation (SD) for both TMZ and 
Patrin-2 were found to be 4.46 and 7.02, respectively, and the related standard deviation 
(RSD) for both TMZ and Patrin-2 was found to be 0.37 and 1.28, respectively. As the 
RSD values for both the compounds were low the repeatability was acceptable. 
Table 3.2 The repeatability results for TMZ and Patrin-2 at concentration of 0.02 
mg/ml. The mean of the 6 injections was calculated from which the SD and RSD values 
are obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   
 
                   
                  SD-Standard deviation 
                  RSD-Relative standard deviation 
 
 
 
 
No. of injections 
of the sample 
TMZ (0.02 mg/ml) 
Peak Area 
Patrin-2 (0.02 
mg/ml ) 
Peak Area 
1 1208.46 548.26 
2 1214.39 540.00 
3 1201.89 556.08 
4 1206.48 544.25 
5 1210.73 549.99 
6 1212.17 558.62 
Mean 
 
1209.02 
 
549.507 
 
SD 4.456 7.01 
 
RSD 0.37 1.28 
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3.1.3 Reproducibility 
The results obtained from the reproducibility determination of TMZ and Patrin-2 was 
carried out using six samples at a concentration of 0.02 mg/ml (Table 3.3). The SD for 
both TMZ and Patrin-2 were found to be 5.34 and 4.04, respectively, and RSD for both 
TMZ and Patrin-2 were found to be 0.44 and 0.73 respectively. The results obtained can 
be considered as reproducible as a low RSD value was obtained for both the 
compounds. 
Table 3.3 The reproducibility results for TMZ and Patrin-2 at a concentration of 0.02 
mg/ml. The mean of the 6 samples was calculated from which the SD and RSD values 
are obtained. Data values are the average of n= 3. 
 
 
Sample No. 
 
TMZ (0.02 mg/ml) 
Peak area 
Patrin-2 (0.02 
mg/ml) 
Peak area 
1 1206.17 554.19 
2 1210.62 558.18 
3 1213.87 548.26 
4 1201.23 549.13 
5 1214.47 556.66 
6 1204.54 555.26 
Mean 1208.48 553.61 
 
SD 5.34 4.04 
 
RSD 0.44 0.73 
                 SD-standard deviation 
                 RSD- Relative standard deviation 
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3.1.4 Limit of detection 
LOD for both TMZ and Patrin-2 were found to be 3.90 µg/ml. As the injection was not 
repeatable at the concentration of 3.90 µg/ml, however, a small peak could be detected 
for qualitative purposes but cannot be quantified. 
Table 3.4 Limit of detection for TMZ and Patrin-2. Data values are the average of         
n = 3. 
 
Concentration (µg/ml) TMZ 
MPA 
Patrin-2 
MPA 
500 300.81 117.45 
250 151.23 55.73 
125 60.40 25.14 
62.5 29.30 12.24 
31.25 14.03 5.85 
15.62 7.08 3.88 
7.81 3.46 1.69 
3.91 1.63 0.845 
                MPA- Mean Peak Area. 
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3.1.5 Limit of quantification 
The LOQ for both TMZ and Patrin-2 were 7.81 µg/ml and therefore the SD for both 
TMZ and Patrin-2 were found to be 0.05 and RSD for both TMZ and Patrin-2 were 
found to be 1.43 and 3.17, respectively. 
Table 3.5 Limit of quantification of TMZ and Patrin-2 at a concentration of 7.81 µg/ml 
was injected 6 times. The mean of the 6 injections was calculated from which the SD 
and RSD values are obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   SD-standard deviation 
                   RSD- Relative standard deviation 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. of 
injections 
TMZ 
Peak Area 
Patrin-2 
Peak Area 
1 3.58 1.64 
2 3.49 1.58 
3 3.61 1.55 
4 3.52 1.67 
5 3.62 1.57 
6 3.55 1.66 
Mean 3.56 1.61 
SD 0.05 0.05 
 
RSD 1.43 3.17 
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The results obtained from the HPLC analysis for validation of the system are 
summarised (Table 3.6). Thus from these results the HPLC method was considered to 
be reliable for the analysis of TMZ and Patrin-2 and further experiments were carried 
out using both the compounds. 
 
Table 3.6: A summary of the parameters used to validate the analytical HPLC method 
for TMZ and Patrin-2. 
 
Parameters TMZ Patrin-2 
Analytical wavelength 
(nm) 
330 287 
Stock solution (mg/ml) 0.1 0.1 
Retention time (min) 3.5 5.6 
Linearity range 
(mg/ml) 
0.01- 0.1 0.01- 0.1 
Regression equation Y=585.79x + 31.872 Y=333.60x - 138.06 
Correlation coefficient 
(R
2
) 
0.999 0.994 
Repeatability (RSD) 0.37 1.28 
Reproducibility (RSD) 0.44 0.73 
Limit of detection      
(µg/ml) 
3.90 3.90 
Limit of quantification 
(µg/ml) 
7.81 7.81 
Limit of quantification 
(RSD) 
1.43 3.17 
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3.2 Stability test for TMZ and Patrin-2: 
3.2.1 Compatibility test of TMZ and Patrin-2 carried out in mixture of PBS and 
ethanol. 
In order to determine whether TMZ and Patrin-2 were compatible in PBS at a pH of 7.4 
the following tests were carried out. TMZ, Patrin-2 and a combination of TMZ and 
Patrin-2 stock solutions were prepared at a concentration of 0.05 mg/ml in a mixture of 
PBS and ethanol (ratio of 8:2). The three solutions were stored at 25, 37 and 50 °C. 
Rapid degradation of TMZ was observed at 37 and 50 °C, whereas, Patrin-2 showed a 
rapid degradation at 50 °C (Table 3.7 and 3.8). A combination of both TMZ and Patrin-
2 on HPLC analysis indicated rapid degradation products at 25, 37 and 50 °C (Table 
3.9). Reaction between TMZ and patrin-2 has also been previously reported by Ranson 
and his team (Ranson et al., 2007). 
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Degradation products of TMZ were observed at 37 and 50 °C from 72 to 288 hr while at 
25 °C there was small amount of reduction in the peak area but no degradation product 
was detected. 
Table 3.7 The results for the stability of TMZ at a concentration of 0.05 mg/ml in PBS 
and ethanol (ratio 8:2) solution stored for (a) 72 hr (b) 288 hr at three different 
temperatures. The analysis of these samples were carried out using the HPLC with 
mobile phase (0.5 % acetic acid:methanol in the ratio of 9:1). Data values are the 
average of n = 3. 
Temperature 
(°C) 
Time 
(hr) 
Retention time 
(min) 
MPA 
 
Compound  
25 72 2.08 2504.09 TMZ  
288 7.43 1160.87 UDP  
37 72 
2.05 
2.22 
594.87 
268.32 
TMZ 
UDP 
288 
2.15 
6.13 
17.50 
12.79 
21.90 
1139.25 
TMZ 
UDP  
UDP 
50 72 
2.02 
2.17 
137.66 
72.46 
TMZ 
UDP 
288 
2.17 
6.35 
17.50 
19.33 
18.39 
1115.70 
TMZ 
UDP  
UDP 
                  MPA- Mean Peak Area. 
                  UDP- Unidentified Degradation Product. 
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Degradation products of Patrin-2 unlike TMZ were observed at 50 °C from 72 to 288 hr 
while at 25 and 37 °C there was small amount of reduction in the peak area at 72 hr but 
no degradation product was detected. 
Table 3.8 The results for the stability of Patrin-2 at a concentration of 0.05 mg/ml in 
PBS and ethanol (ratio 8:2) solution stored for (a) 72 hr (b) 288 hr at three different 
temperatures. The analysis of these samples was carried out using HPLC with mobile 
phase (35 % acetonitrile consisting of 10 mM TBAA, 10 mM SDS and 25 mM citric 
acid). Data values are the average of n = 3. 
Temperature 
(°C) 
Time 
(hr) 
Retention time 
(min) 
MPA Compound 
25 72 6.72 1620.24 Patrin-2 
288 
2.47 
3.77 
4.67 
5.93 
65.91 
10.79 
31.77 
1417.69 
UDP 
UDP 
UDP 
Patrin-2 
37 72 6.97 1042.62 Patrin-2 
288 
2.03 
3.73 
4.22 
4.63 
5.90 
779.86 
77.85 
21.05 
36.28 
432.08 
UDP 
UDP 
UDP 
UDP 
Patrin-2 
50 72 
2.07 
7.02 
753.51 
432.11 
UDP 
Patrin-2 
288 
2.03 
3.73 
4.22 
6.18 
607.63 
87.29 
36.85 
136.64 
UDP 
UDP 
UDP 
Patrin-2 
                   MPA- Mean Peak Area. 
                   UDP- Unidentified Degradation Product. 
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Rapid degradation products of TMZ and Patrin-2 on their combination were observed 
from 72 hr at all three temperatures 25, 37 and 50 °C with large amount of reduction in 
the peak areas of TMZ and Patrin-2. Thus the HPLC analysis of TMZ, Patrin-2 and 
combination of both indicated that TMZ and Patrin-2 are not stable together. 
Table 3.9 The results for the compatibility of TMZ and Patrin-2 at a concentration of    
0.05 mg/ml in PBS and ethanol (ratio 8:2) solution stored for (a) 72 hr (b) 288 hr at 
three different temperatures. The analysis of these samples were carried out using 
HPLC with mobile phase (35 % acetonitrile consisting of 10 mM TBAA, 10 mM SDS 
and 25 mM citric acid). Data values are the average of n = 3. 
Temperature 
(°C) 
Time 
(hr) 
Retention time 
(min) 
MPA 
 
Compound 
25 72 
2.03 
6.57 
7.65 
1459.65 
1253.87 
319.64 
TMZ 
Patrin-2 
UDP 
288 
2.18 
4.12 
4.58 
10.10 
231.41 
320.23 
163.23 
533.06 
TMZ 
UDP  
UDP 
UDP 
37 72 
2.57 
2.93 
6.62 
499.12 
342.71 
1208.92 
TMZ 
UDP  
Patrin-2 
288 
2.37 
2.82 
4.35 
6.18 
3128.12 
762.41 
484.07 
458.80 
TMZ 
UDP  
UDP 
Patrin-2 
50 72 
2.60 
2.98 
7.00 
443.66 
356.38 
697.83 
TMZ 
UDP  
Patrin-2 
288 
2.02 
2.43 
2.77 
3.73 
4.20 
6.13 
738.84 
494.62 
416.74 
120.69 
48.11 
195.94 
TMZ 
UDP  
UDP 
UDP  
UDP 
Patrin-2 
                   MPA- Mean Peak Area. 
                   UDP- Unidentified Degradation Product. 
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(a) 
 
 
(b) 
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(c) 
 
Figure 3.2 HPLC chromatogram for the compatibility of TMZ and Patrin-2 at a concentration 
of 0.05 mg/ml (a) TMZ Standard solution in mobile phase (n = 3), (b) Patrin-2 standard 
solution in acetonitrile (n = 3) and (c) TMZ and Patrin-2 mixture in PBS and ethanol (ratio 
8:2) solution stored for 288 hr at 37°C  (n = 3). 
 
3.2.2 Dry sample reaction carried out for the determination of compatibility of 
TMZ and Patrin-2 at 50 °C.  
When 10 mg of TMZ and 10 mg of Patrin-2 were mixed and subjected to stress 
conditions at 50 °C for a period of 1 week, both compounds were solubilised in a 
mixture of PBS and ethanol (ratio of 8:2) and a concentration made up to 0.05 mg/ml. 
HPLC analysis clearly indicated that degradation had occurred and thus provided 
further evidence that proved TMZ and Patrin-2 to be incompatible. 
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Table 3.10 The results testing the compatibility of TMZ and Patrin-2 at a concentration 
of 0.05 mg/ml in PBS and ethanol solution. The analysis of this sample was carried out 
using HPLC with mobile phase (35 % acetonitrile consisting of 10 mM TBAA, 10 mM 
SDS and 25 mM citric acid). Data values are the average of n = 3. 
Concentration  
(mg/ml) 
Retention time 
(min) 
MPA 
 
Compound  
0.05 
2.50 
2.87 
4.02 
4.98 
6.43 
310.06 
329.33 
4.39 
5.86 
972.39 
TMZ  
UDP  
UDP 
UDP 
Patrin-2  
                         MPA- Mean Peak Area. 
                       UDP- Unidentified Degradation Product. 
 
3.3 Results of attempted preparations of various liposome formulations using TMZ 
as the active compound. 
3.3.1 Freeze-Thaw method.  
The liposomal formulation of TMZ was carried out by combining 10 mg of TMZ with 
phospholipids in different ratios and also using the combination of phospholipids and 
cholesterol to maximise the entrapment of TMZ. The lowest EE % obtained using the      
freeze-thaw method was with the use of DMPC and TMZ, use of other phospholipids 
such as lα-phosphatidylcholine, lecithin, phospholipon 90H and DSPC also did not 
proved to be suitable to give a better EE % (Table 3.11).  
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Table 3.11 Entrapment efficiency of TMZ loaded liposomes using different phospholipids using the freeze-thaw method. Data values ± 
standard deviation are average of n = 3. 
EE %- Entrapment efficiency 
 
 
 
 
Ratio 
 
 
TMZ:  Lα-
phosphatidylcholine 
 
 
TMZ: DSPC 
 
 
TMZ:DMPC 
 
 
TMZ: Phospholipon 
90H 
 
 
TMZ:Lecithin 
 
EE % 
 
Average 
Particle   
size (µm) 
 
EE % 
Average 
Particle 
size (µm) 
 
EE % 
Average 
Particle 
size (µm) 
 
EE % 
Average 
Particle 
size (µm) 
 
EE % 
Average 
Particle 
size (µm) 
 
 
1:1 
 
 
 
1.15 ± 0.15 
 
 
3.911 
 
 
1.78 ± 1.15 
 
 
5.352 
 
 
0.56 ± 0.55 
 
 
2.821 
 
 
0.60 ± 0.36 
 
 
7.099 
 
 
1.3 ± 0.10 
 
 
4.078 
 
 
1:2 
 
 
 
1.21 ± 0.14 
 
 
3.719 
 
 
0.77 ± 0.40 
 
 
6.979 
 
 
0.17 ± 0.11 
 
 
2.762 
 
 
0.92 ± 0.42 
 
 
7.229 
 
 
2.1 ± 1.95 
 
 
4.066 
 
 
1:3 
 
 
 
1.24 ± 0.21 
 
 
5.368 
 
 
0.63 ± 0.19 
 
 
6.570 
 
 
0.15 ± 0.16 
 
 
3.692 
 
 
3.64 ± 1.36 
 
 
7.195 
 
 
2.5 ± 1.47 
 
 
4.248 
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The combination of phospholipids and cholesterol was experimented to improve the   
EE % of TMZ (Table 3.12). The combination of phospholipon 90H and cholesterol was 
analysed to give the maximum entrapment of 11.54 ± 0.67 % from the freeze-thaw 
method while the combination of lα-phosphatidylcholine and cholesterol did not 
indicate any difference in the EE % of TMZ when compared to the EE % of TMZ with 
lα-phosphatidylcholine (Table 3.11 and 3.12). 
Table 3.12 Entrapment efficiency of TMZ loaded liposomes with a combination of 
phospholipon 90H and cholesterol and a combination of lα-phosphatidylcholine and 
cholesterol using the freeze-thaw method. Data values ± standard deviation are average 
of n = 3. 
EE %: Entrapment efficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ratio 
 
TMZ: Phospholipon 90H: 
Cholesterol 
 
TMZ:  Lα-phosphatidylcholine 
: 
Cholesterol 
 
EE % 
Average 
Particle size 
(µm) 
 
EE % 
Average  
Particle size 
(µm) 
 
1:1:1 
 
7.56 ± 1.06 
 
7.752 
 
0.98 ± 0.61 
 
6.821 
 
1:2:1 
 
6.32 ± 3.73 
 
6.078 
 
1.13 ± 0.16 
 
6.799 
 
1:2:2 
 
11.54 ± 0.67 
 
10.654 
 
0.74 ± 0.37 
 
6.910 
 
1:3:1 
 
11.02 ± 0.60 
 
9.086 
 
0.84 ± 0.44 
 
5.912 
 
1:3:2 
 
10.38 ± 0.54 
 
9.002 
 
0.91 ± 0.75 
 
6.871 
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3.3.2 Dehydration-Rehydration method.  
The liposomal formulation of TMZ was carried out by combining 10 mg of TMZ with 
phospholipids in different ratios and also using a combination of phospholipids and 
cholesterol/stearic acid in order to optimise the entrapment of TMZ. Use of 
phospholipids alone with TMZ did not proved to be suitable to give a better EE % of 
TMZ (Table 3.13).  
Table 3.13 Entrapment efficiency achieved from TMZ loaded liposomes with the 
phospholipids using the dehydration-rehydration method. Data values ± standard 
deviation are average of n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         EE %: Entrapment efficiency 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ratio 
 
 
TMZ: Phospholipon 90H 
 
 
TMZ: Lecithin 
 
EE % 
 
Average 
Particle   
size (µm) 
 
EE % 
Average 
Particle 
size (µm) 
 
 
1:1 
 
 
 
0.27 ± 0.16 
 
 
7.116 
 
 
0.57 ± 0.31 
 
 
6.019 
 
 
1:2 
 
 
 
0.25 ± 0.11 
 
 
7.119 
 
 
0.45 ± 0.33 
 
 
7.062 
 
 
1:3 
 
 
 
0.24 ± 0.20 
 
 
7.231 
 
 
0.53 ± 0.09 
 
 
7.023 
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The combination of phospholipids and cholesterol was optimised to improve the EE % 
of TMZ (Table 3.14). A combination of phospholipon 90H and cholesterol was found to 
provide a maximum entrapment of 26.69 ± 0.34 % from the dehydration-rehydration 
method. 
Table 3.14 Entrapment efficiency achieved from TMZ loaded liposome with the 
phospholipids in combination with cholesterol using the dehydration-rehydration 
method. Data values ± standard deviation are average of n = 3. 
 
EE %: Entrapment efficiency 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ratio 
 
TMZ:Phospholipon 90H: 
Cholesterol 
 
TMZ:Lecithin: 
Cholesterol 
 
EE % 
 
Particle size 
(µm) 
 
EE % 
 
Particle size 
(µm) 
 
1:1:1 
 
2.43 ± 1.40 
 
7.341 
 
0.50 ± 0.54 
 
7.189 
 
1:2:1 
 
2.25 ± 1.35 
 
7.412 
 
0.51 ± 0.60 
 
7.061 
 
1:2:2 
 
26.69 ± 0.34 
 
 
12.306 
 
1.16 ± 0.11 
 
7.621 
 
1:3:1 
 
13.61 ± 1.16 
 
7.089 
 
0.23 ± 0.08 
 
7.168 
 
1:3:2 
 
19.36 ± 2.13 
 
7.921 
 
0.67 ± 0.46 
 
7.211 
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The combination of phospholipids and stearic acid was experimented to for similar 
reasons as for cholesterol. The combination of phospholipon 90H and stearic acid did 
not indicate any difference in the EE % of TMZ when compared to the EE % of TMZ 
with phospholipon 90H while the combination of lecithin and stearic acid showed 
increase in the EE % as compared to the EE % of TMZ with lecithin (Table 3.13 and 
3.15). 
Table 3.15 Entrapment efficiency achieved from TMZ loaded liposome with 
phospholipids mentioned in the table below in combination with stearic acid using the 
dehydration-rehydration method. Data values ± standard deviation are average of n = 3. 
EE %: Entrapment efficiency 
 
 
 
 
 
 
 
 
 
Ratio 
 
TMZ: Phospholipon 90H: Stearic 
acid 
 
TMZ: Lecithin: Stearic  
acid 
 
EE % 
Average 
Particle            
size(µm) 
 
EE % 
Average 
Particle            
size(µm) 
 
1:1:1 
 
1.01 ± 0.35 
 
6.834 
 
1.98 ± 0.24 
 
6.985 
 
1:2:1 
 
0.95 ± 0.33 
 
5.126 
 
4.94 ± 0.41 
 
6.519 
 
1:2:2 
 
1.09 ± 0.24 
 
5.981 
 
2.73 ± 0.27 
 
7.106 
 
1:3:1 
 
1.11 ± 0.19 
 
6.286 
 
5.09 ± 0.67 
 
7.135 
 
1:3:2 
 
0.98 ± 0.30 
 
6.121 
 
6.65 ± 1.86 
 
7.083 
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3.3.3 A comparison between Freeze-thaw and Dehydration-Rehydration methods 
used for the preparation TMZ loaded liposomes. 
Different ratios of phospholipon 90H and combinations of phospholipon 90H with 
cholesterol were used in order to prepare TMZ loaded liposomes. In the experiment 
involving the freeze-thaw method there was a significant increase (*, P<0.005) in the 
EE % when a combination of phospholipon 90H and cholesterol was used at ratios of 
1:2:2, 1:3:1 and 1:3:3 compared to the other ratios. In the dehydration-rehydration 
method, similar to freeze-thaw method a combination of phospholipon 90H and 
cholesterol showed the maximum EE %. As shown in the Fig. 3.2 there is a significant 
increase (**, P<0.001) in the EE % at a ratio 1:2:2, while the ratios 1:3:1 and 1:3:2 
showed an increase in the EE % compared to the other ratios, however, there was a 
significant decrease (*, P<0.005) in the EE % compared with the ratio 1:2:2                
(**, P<0.001). On comparing the freeze-thaw and dehydration-rehydration methods 
using a 1:2:2 ratio, the dehydration-rehydration method showed a significant increase              
(**, P<0.001) in the EE % as opposed to a *, P<0.005 value for the freeze-thaw 
method.  
 
Figure 3.3 Comparison between Freeze-Thaw and Dehydration-Rehydration method. The 
effect of different ratios of phospholipon 90H and on combining it with cholesterol in order to 
encapsulate TMZ comparing two methods freeze-thaw and dehydration-rehydration using a 
1:2:2 ratio, the dehydration-rehydration method showed a significant increase (**, P<0.001) in 
the EE % as opposed to a P<0.005 value for the freeze-thaw method. Data obtained are 
expressed as mean ± S.D of EE %, where n = 3. 
97 
 
3.4 Preparation of PLGA microparticles using two procedures. 
Microparticles were prepared using PLGA of different molecular weights (MW). Two 
procedures were used for the preparation of the microparticles. However, in both 
procedures PLGA with an average molecular weight (MW) of 1.7x10
4
 Da showed 
maximum entrapment of TMZ. 
3.4.1 Emulsifying-Solvent Evaporation method. 
In order to prepare TMZ loaded PLGA microparticles the emulsifying solvent 
evaporation method was used. The maximum entrapment achieved using this method 
was not more than 2.76 ± 0.36 %, however modification in this technique and as from 
the literature it is possible to obtain the preparation of TMZ loaded PLGA 
microparticles with better EE% (Zhang and Gao, 2007). 
Table 3.16 The entrapment efficiencies achieved when TMZ was used to prepare 
PLGA microparticles using the emulsifying solvent evaporation method and varying the 
MW of PLGA. The PLGA with a MW of 1.7 x 10
4
 Da showed the maximum 
entrapment of TMZ. Data values ± standard deviation are average of n = 3. 
 
PLGA 
MW (Da) 
 
EE % 
        1.7x10
4
 
 
2.76 ± 0.36 
 
1.5x10
4
- 4x10
4
 
 
2.56 ± 0.10 
 
4x10
4
- 7.5x10
4
 
 
2.01 ± 0.36 
 
6.6x10
4
- 1x10
5
 
 
1.62 ± 0.39 
                                       PLGA- Poly (DL-lactide-co-glycolide) 
                                       MW- Molecular weight 
                                       Da- Dalton 
                                       EE %- Entrapment efficiency  
 
From the HPLC analysis the mean peak area of the standard solution used to calculate 
the EE % was 6456.41. 
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3.4.2 Spray dry method 
Spray dry method used for obtaining TMZ loaded PLGA microparticles and 
Patrin-2 loaded PLGA microparticles. 
The spray dry method was used to prepare microparticles of both TMZ and Patrin-2 
using PLGA as the vehicle. Maximum entrapment using this method was achieved 
when TMZ was used affording a 64.32 ± 2.58 % encapsulation efficiency while for 
Patrin-2 a 68.47 ± 1.47 % encapsulation efficiency was achieved. Thus this technique 
was found to be successful for the preparation of both TMZ and Patrin-2 loaded PLGA 
microparticles. However the analytical method used for calculation needs improvement 
in order to obtain higher encapsulation. 
Table 3.17 The entrapment efficiency obtained from TMZ loaded PLGA microparticles 
and Patrin-2 loaded PLGA microparticles by varying the MW of PLGA using the Spray 
Dry method with PLGA of MW 1.7 x 10
4
 Da showed the maximum entrapment with 
TMZ. Data values ± standard deviation are average of n = 3. 
 
PLGA 
MW (Da) 
 
TMZ 
 EE % 
 
 
Patrin-2 
EE % 
 
        1.7x10
4
 
 
64.32 ± 2.58 
 
68.47 ± 1.47 
 
1.5x10
4
- 4x10
4
 
 
18.77 ± 0.67 
 
24.76 ± 1.46 
 
4x10
4
- 7.5x10
4
 
 
19.35 ± 1.92 
 
6.65 ± 0.90 
 
6.6x10
4
- 1x10
5
 
 
12.15 ± 2.14 
 
3.20 ± 0.17 
                     PLGA- Poly (DL-lactide-co-glycolide) 
                     MW- Molecular weight 
                     Da-Dalton 
                     EE %- Entrapment efficiency  
 
From the HPLC analysis, the mean peak area of the standard solution for TMZ and 
Patrin-2 used to calculate the EE % was 3832.56 and 8023.08, respectively. 
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(a) 
 
 
(b) 
 
Figure 3.4 Spray dry method. The effect of varying MW of PLGA used for encapsulation of 
(a) TMZ and (b) Patrin-2 using Spray Dry method. Both TMZ and Patrin-2 gave maximum 
entrapment with the PLGA of MW of 1.7x10
4
 Da. Data obtained are expressed as mean ± S.D 
of EE %, where n = 3. 
 
 
 
100 
 
3.5 Particle size analysis of liposome and microparticles: 
3.5.1 Particle size analysis of liposome using the mastersizer. 
Liposomes prepared by the freeze-thaw and dehydration-rehydration method were 
analysed using the mastersizer. The maximum entrapment of TMZ in liposomes was 
achieved by using a combination of phospholipon 90H and cholesterol in both the 
methods.     (Fig. 3.4). 
(a) 
 
(b) 
 
 
Figure 3.5 Particle size distributions. (a) Particle size of the TMZ loaded liposome consisting 
of phospholipon 90H and cholesterol using the freeze-thaw method is 10.654 µm. (b) Particle 
size of the TMZ loaded liposome consisting of phospholipon 90H and cholesterol using the 
dehydration-rehydration method is 12.306 µm. 
3.5.2 Particle size analysis of microparticles using the Scanning Electron 
Microscopy (SEM). 
The technique was applied for measuring microparticles prepared by the emulsifying-
solvent evaporation and the spray dry method. Maximum entrapment of TMZ loaded 
PLGA microparticles and Patrin-2 loaded PLGA microparticles were achieved using the 
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spray dry method with the PLGA of MW of 1.7x10
4
 Da. The microparticles were found 
to be spherical in shape (Fig. 3.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a)                                                                   (b) 
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(c)                                                                     (d) 
           
 
(e)                                                                     (f) 
           
 
Figure 3.6 Particle size analyses. The particle size and morphology of the TMZ loaded PLGA 
microparticles are shown in Fig. (a), (b) and (c) while for Patrin-2 loaded PLGA microparticles 
is shown in Fig. (d), (e) and (f). The particles appear to be amorphous, smooth and spherical in 
shape. However, TMZ microparticles shown in (b) indicates small amount of pore formation on 
the surface of the microparticles. 
 
 
 
3.6 Dissolution techniques 
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The dispersion and dialysis method were used to monitor the release of TMZ and 
Patrin-2 from the PLGA microparticles. 
3.6.1.1 Dispersion Method used for determining the release of TMZ from the 
microparticles. 
The release profile of TMZ from PLGA microparticles was monitored in PBS, pH 7.4 at    
37 ± 0.5 °C. A plot of the percentage cumulative amount released of TMZ against time 
(Fig. 3.6) was obtained. From the release profiles, it was found that an initial burst of 
TMZ release was during the first 30 min of analysis followed by a gradual decrease in 
the concentration of TMZ. The cumulative mass of TMZ was calculated at 0.5 hr which 
is 407.06 µg in concentration as shown in Table 3.18, however, the total amount of 
TMZ theoretically present in TMZ loaded PLGA particles at the beginning of the in 
vitro release was 1200 µg. As degradation of the drug takes place are when kept at      
37 °C could be the reason for not obtaining the expected amount. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.18 From HPLC analysis TMZ release from PLGA microparticles was detected 
and from the peak area obtained the cumulative mass release was calculated. Data value 
are the average of n = 2. 
104 
 
Time 
(hr) 
MPA 
 
Cumulative mass 
release (µg) 
0.5 985.52 407.06 
1 914.95 393.22 
2 603.32 275.28 
4 248.99 133.79 
6 116.22 80.83 
12 30.4 45.64 
24 6.56 35.44 
48 4.29 34.03 
72 3.14 33.07 
96 3.09 32.56 
120 3.04 32.05 
144 2.95 31.52 
168 2.82 30.97 
192 2.29 30.25 
216 Not detected Not detected 
              MPA-Mean Peak Area 
 
 
 
 
 
 
 
 
 
 
 
 
The percentage of cumulative release of TMZ against time (Fig. 3.6) was plotted 
indicating the release pattern of TMZ. During the first 30 minutes of analysis TMZ 
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showed an initial burst followed by a gradual decrease in the concentration of TMZ 
which could be due to degradation of the drug at 37 °C. 
 
 
Figure 3.7 Release pattern of TMZ from PLGA microparticles. TMZ released from PLGA 
microparticles in PBS at pH 7.4 and at 37 ± 0.5 °C using the dispersion method. 
 
 
 
 
 
 
 
 
 
 
3.6.1.2 Dispersion Method used for determining the release of Patrin-2 from 
microparticles. 
0
20
40
60
80
100
120
0 50 100 150 200 250
C
u
m
u
la
ti
ve
 re
le
as
e
(%
 )
Time (hr)
Temozolomide
106 
 
The release profile of Patrin-2 from PLGA microparticles in PBS at pH 7.4 and at        
37 ± 0.5 °C. A plot of the percentage cumulative release of Patrin-2 against time       
(Fig. 3.7) was obtained. From the release profile, it was found that the release rate of 
Patrin-2 was slow with an initial burst of Patrin-2 released followed by an increase in 
peak area i.e. increase in concentration of Patrin-2. The cumulative mass of Patrin-2 was 
calculated the highest amount was equivalent to 196.16 µg as shown in Table 3.19, 
however the total amount of Patrin-2 theoretically present in TMZ loaded PLGA 
particles at the beginning of the in vitro release was 1500 µg. As degradation of the drug 
takes place are when kept at 37 °C could be the reason for not obtaining the expected 
amount. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.19 Patrin-2 released from PLGA microparticles was detected and from the peak 
area obtained the cumulative mass was calculated. Data value are the average of n = 2. 
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Time 
(hr) 
MPA 
 
Cumulative mass 
release (µg) 
0.5 22.87 120.56 
1 23.89 126.14 
2 33.35 138.08 
4 45.75 152.51 
6 44.42 157.03 
12 48.95 165.89 
24 65.26 183.71 
48 69.4 192.91 
72 58.91 191.27 
96 51.18 191.38 
120 50 196.16 
144 40.51 194.69 
168 12.69 179.19 
192 19.44 188.77 
216 24.69 189.40 
240 25.19 189.90 
264 29.43 190.52 
288 31.01 191.07 
312 Not detected Not detected 
               MPA-Mean Peak Area. 
 
 
 
 
 
 
 
 
 
 
 
 
The percentage of cumulative release of Patrin-2 against time (Fig. 3.7) was plotted 
indicating the release pattern of Patrin-2. During the first 30 min of analysis Patrin-2 
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showed an initial burst followed by a slow increase in peak area i.e. increase in 
concentration of Patrin-2 which could be due to degradation of the drug at 37 °C.  
    
 
 
Figure 3.8 Release pattern of Patrin-2 from PLGA microparticles. Patrin-2 released from 
PLGA microparticles in PBS at pH 7.4 and at 37 ± 0.5 °C using dispersion method.  
 
 
 
 
 
 
 
 
 
3.6.2 Dialysis Bag Method used for determining the release of TMZ and Patrin-2 
from microparticles. 
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The release profiles of TMZ and Patrin-2 from PLGA microparticles in PBS at a pH 7.4 
and at a temperature of 37 ± 0.5 °C. The results were analysed using HPLC. The peak 
area obtained for both TMZ and Patrin-2 was too low to carry out the cumulative 
amount released. The peak area of the control as well for both TMZ and Patrin-2 was 
found to be low. 
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CHAPTER 4 
DISCUSSION, CONCLUSION  
AND FUTURE PROSPECTS 
 
 
 
 
 
 
 
 
4.1 Validation of HPLC system  
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A validation of the HPLC method was carried out following standard procedures using 
validation of compendial methods of USP. The mobile phase selection for TMZ was 
carried out by referring to a previously established method, i.e. 0.5 % acetic 
acid:methanol in the ratio of 9:1 (pH 2.8) while 35 % acetonitrile consisting of 10 mM 
TBAA, 10 mM SDS and 25 mM citric acid (pH 3.4) was found to be suitable selection 
of mobile phase for analysis of Patrin-2 (Moffat et al., 2004; Shervington et al., 2005). 
The retention time of TMZ was found to be 3.7 min while Patrin-2 the retention time 
was found to be 5.6 min. A calibration curve measuring the peak area against six 
concentrations for TMZ and Patrin-2 were found to be linear in the range investigated. 
The regression coefficient, R
2 
values for TMZ and Patrin-2 were found to be 0.999 and 
0.994, respectively. The SD and RSD indicated acceptable precision of the methods and 
the limit of detection (LOD) and limit of quantification (LOQ) were determined (Table 
3.6). The LOD and LOQ concentration of TMZ and Patrin-2 was found to be the same 
which is possible as both the compounds are chromophores responsible for DNA 
cleavage (Shen et al., 1995). Based on the data obtained from the validation procedures, 
the methods were found suitable for carrying out the experiments involving the 
preparations of liposome and microparticles. 
4.2 Stability test of TMZ and Patrin-2: 
An initial compatibility test was carried out to investigate whether TMZ and Patrin-2 
could be formulated together. Thus, to ensure the stability of TMZ and Patrin-2, both 
the compounds were stored individually and as a mixture in PBS and ethanol (ratio of 
8:2) at pH 7.4 at temperature 25, 37 and 50 °C. Rapid degradation of TMZ was 
observed at both 37 and 50 °C when stored for 72 hr, whereas Patrin-2 showed 
excessive degradation after storage at 50 °C for 72 hr. When in combination both TMZ 
and Patrin-2 showed early and rapid degradation at all three incubating temperatures at 
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a period of 72 hr. Powdered samples of TMZ and Patrin-2 were also stored at 50 °C for 
1 week and then analysed after solubilising in PBS/ ethanol (8:2) at pH 7.4. Although 
there was a considerable quantity of both TMZ and Patrin-2 intact, there were several 
peaks observed that corresponded to degradation products (Table 3.10). Based on these 
observations, a personal communication and a previous report by Ranson and his team it 
was decided not to combine TMZ and Patrin-2 for preparing of either liposomes or 
PLGA microparticles (Ranson et al., 2007). Ranson et al also reported that TMZ and 
Patrin-2 when given in combination to the patient results in increased incidence of 
haematological adverse events like thrombocytopenia and neutropenia                 
(Ranson et al., 2007). 
 
4.3 Attempted preparation of various liposome formulation of TMZ using freeze-
thaw and dehydration-rehydration method. 
Different ratios of phospholipid individually as well as in combination with cholesterol 
were used to prepare TMZ loaded liposomes. It was observed that the EE % varied from 
one phospholipid to another, Ostro, 1983 also reported similar observations. The highest 
value of EE % calculated for this method was found when phospholipon 90H and 
cholesterol were used, while the lowest EE % was estabilished when liposomes were 
prepared with DMPC. The differences may be due to the variation in the phase 
transition temperatures and in the acyl chain length (Anderson and Omri, 2004).  As 
shown in Fig. 1.13 phospholipon 90H has longer acyl chain and higher phase transition 
temperature (54 °C) compared to DMPC (Fig. 1.11b). Phospholipon 90H was 
comparatively better than DMPC, however, when phospholipon 90H was used alone 
there was no improvement in the EE %, and hence was combined with cholesterol 
(shown in Fig. 3.2). The maximum EE % achieved using this method was still rather 
low, with a maximum value of 11.54 ± 0.67 %. This may have been attributed to the 
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low affinity and solubility of TMZ with the lipid which constitutes the liposomal 
membrane increasing the chances of TMZ being entrapped in the aqueous compartment, 
thus, less amount of medium entrapped gives lower EE % (Vadiei et al., 1989; Gulati et 
al., 1998). Hence, the use of cholesterol increases the EE % as it makes the membrane 
more rigid and reduces the drug from escaping (Liu et al., 2002). 
Similar to the freeze-thaw method different ratios of phospholipid were used in addition 
to combinations with cholesterol/stearic acid to prepare TMZ loaded liposomes using 
dehydration-rehydration method. The highest of EE % obtained was when TMZ: 
phospholipion 90H: cholesterol in a ratio 1:2:2 was used achieving 26.69 ± 0.34 %. 
When TMZ and phospholipon 90H was used, the EE % was very low. Cholesterol was 
included in the formulation in order to increase the strength of the membrane. With the 
inclusion of stearic acid there was no significant improvement in the EE %             
(Gomez-hens and Fernandez- Romero, 2005). Thus showing cholesterol to be more 
suitable for preparing TMZ loaded liposomes. Although the EE % achieved with 
phospholipon 90H and cholesterol was not high, this may have been attributed to the 
low affinity and solubility of TMZ with the lipid (Vadiei et al., 1989; Gulati et al., 
1998).  
On comparing the EE % between freeze-thaw and dehydration-rehydration methods 
using the same concentration of phospholipids and TMZ, the EE % achieved by the 
dehydration-rehydration method was up to twice that of the freeze-thaw method (Refer 
to result section: 3.3.3). This could have been attributed to the dehydration-rehydration 
method involving the simultaneous trapping of most of the components. The membrane 
boundaries of the vesicles are reported to protect the encapsulated material under 
extreme conditions (Monnard et al., 1997). Important features of the two methods in 
addition to significant entrapment of the active compound is the broad range of 
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biologically active agents that can be used and liposomes prepared present stable solute 
retention characteristics. These two methods are relatively simple and do not require use 
of organic solvents or detergents (Ostro, 1983l; Mayer et al., 1986). In this study 
different ratios of phospholipid were used individually as well as in combination with 
cholesterol/stearic acid were used in both the methods. However, a combination of 
phospholipon 90H together with cholesterol showed maximum entrapment in both 
methods. In the freeze-thaw method there was a significant increase (*, P<0.005) in the 
EE % when a combination of TMZ, phospholipon 90H and cholesterol were used at 
ratios of 1:2:2, 1:3:1 and 1:3:3 (Refer to result section: 3.3.3). When only TMZ and 
phospholipon 90H were used at ratios of 1:1, 1:2 and 1:3 low entrapment of TMZ was 
achieved as shown in Fig 3.2 which reinforced the importance of the use of cholesterol. 
In dehydration-rehydration method using similar combinations to the freeze-thaw 
method the combination of phospholipon 90H and cholesterol showed maximum EE %. 
As shown in the Fig. 3.2 there is a significant increase (**, P<0.001) in the EE % at 
1:2:2 ratio, while the 1:3:1 and 1:3:2 ratios showed less significant increase                  
(*, P< 0.005) in the EE % when compared to other ratios such as  1:1:1 and 1:2:1 as 
well as with ratios of phospholipon 90H alone with  TMZ i.e. 1:1, 1:2 and 1:3. In 
comparing the EE % shown in table 3.13 and 3.14, a combination of the ratios of 
phospholipon 90H alone with TMZ is considerably low compared to the combination of 
phospholipon90H and cholesterol with TMZ (Ostro, 1983; Gomez-hens and  
Fernandez- Romero, 2005). Similar to the freeze-thaw method, it justifies that the use of 
cholesterol supports the increase of EE % of TMZ and also according to the results 
obtained as mentioned in table 3.14 and 3.15, cholesterol is useful in increasing the 
rigidity of the membrane (Bangham et al., 1965; Ostro, 1983). It was found that the 
dehydration-rehydration method was found to be more suitable for encapsulating TMZ 
when compared to freeze-thaw method. From the results obtained it was found that the 
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phospholipids and the methods used were not useful for the encapsulation of TMZ into 
liposomes which might be due to TMZ’s high solubility in aqueous medium and low 
affinity with the lipids. Therefore, the investigation was carried out using polymer 
PLGA for preparation of microparticles which are also reported previously to carry 
more advantages over liposomes (Kreuter, 1991). The body distribution of the carriers 
can be altered by modification of their surface properties, especially the surface 
properties of the microparticles are easily changed by simple coating of the particles 
with certain biocompatible surfactants (Bertling et al., 1991). 
4.4 Preparation of PLGA microparticles using emulsifying-solvent evaporation 
and spray dry methods. 
Two methods were used for preparing TMZ loaded PLGA microparticles, one i.e. 
emulsifying solvent evaporation method, while the other, the spray dry method. The 
main aim of this study was to find a suitable method to encapsulate TMZ into 
microparticles and then to combine TMZ with Patrin-2. Because of the mode of action 
of a pseudo substrate i.e. Patrin-2 combining with TMZ would be suitable way of 
enhancing the effect of TMZ, however due to the incompatibility of these two 
compounds described in section 4.2 the strategy was abandoned, microparticles of TMZ 
and Patrin-2 were prepared separately using the spray dry method which gave higher EE 
% than the emulsifying solvent evaporation method. The spray dry method, compared 
with the emulsifying solvent evaporation method, produced more regular shape 
microparticles with a relatively small size distribution, similar observations were also 
reported by Pavanetto et al., 1992.  
TMZ loaded PLGA microparticles were prepared using different MW of PLGA which 
included 1.7x10
4
, 1.5x10
4 - 4x104, 4x104 - 7.5x104 and 6.6x104 - 1x105 using 
emulsifying solvent evaporation method. Though the EE % obtained was very low to be 
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considered, PLGA with MW of 1.7x10
4
 showed EE % of only 2.76 ± 0.36 % which was 
found to be comparatively higher than other PLGA of different MW as shown in table 
3.16. As reported in previous studies, preparation variables can be responsible for 
giving poor EE % such as the selection of the organic solvents or stirring rate of the 
emulsion or sometimes the organic phase acts as a barrier between the internal aqueous 
phase and the continuous aqueous phase (McGinity and O’Donnell, 1997). Due to high 
solubility of some drug in the aqueous medium prevents the preparation of the saturated 
solution in the organic solvents (Herrmann and Bodmeier, 1995). As TMZ is highly 
soluble in aqueous medium these might be the reason responsible for obtaining the low 
entrapment efficiency.  
TMZ loaded PLGA microparticles and Patrin-2 loaded PLGA microparticles were 
prepared by varying the MW of PLGA using the spray dry method, to determine their 
effect on EE % of TMZ. Different molecular weights of PLGA used in the study 
included 1.7x10
4
, 1.5x10
4 - 4x104, 4x104 - 7.5x104 and 6.6x104 - 1x105. The maximum 
entrapment achieved using this method for TMZ was 64.32 ± 2.58 % while for Patrin-2 
the EE % was 68.47 ± 1.47 % thus, this procedure was found to be suitable for the 
preparation of both TMZ loaded PLGA microparticles and Patrin-2 loaded PLGA 
microparticles. On increasing the MW of PLGA i.e. MW in range of 1.5x10
4 
- 4x10
4
, 
4x10
4 
- 7.5x10
4 
and 6.6x10
4 
- 1x10
5
, a significant decrease (*, P< 0.001) in the EE % of 
both TMZ and Patrin-2 is obtained. Previous studies have found that a decrease in the 
EE % could be attributed either to thermal degradation of the compound or the 
accumulation of the active compound on the surface of PLGA microparticles (Sacchetti 
and Van-Oort, 1996; Seong et al., 2003). The main purpose of using the spray dry 
method was to achieve a molecular dispersion of the compound in the final product                
(Takashima et al., 2007; Lee et al., 2008). This method was found to be more effective 
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in producing microspheres with high EE % (Sacchetti and Van-Oort, 1996). As reported 
by previous studies high entrapment efficiency is typical using the spray dry method 
because the drug cannot partition into an external phase as compared to the emulsifying-
solvent evaporation method (O’Hara and Hickey, 2000).  
 
4.5 Particle size analysis of liposomes and microparticles. 
Phospholipids when dispersed in an aqueous medium instantaneously form spherical 
structures called as vesicles or liposomes, having sizes ranging from that of  bacterial 
cells first established by Bangham and co-workers (Bangham et al., 1965). The average 
particle size obtained in this study varied depending on the type of lipids, the 
concentration of the lipids and the EE % or the type of liposome formed. Depending 
upon the liposome formed, as the EE % increases the average particle size increases 
(Table 3.12 and 3.14 and Chou et al., 2003). In the freeze-thaw and dehydration-
rehydration the particle sizes tends to increase slightly on addition of cholesterol.  
The SEM technique was applied for measuring microparticles prepared by emulsifying-
solvent evaporation and the spray dry method. The maximum entrapment of TMZ 
loaded PLGA microparticles and Patrin-2 loaded PLGA microparticles were achieved 
using the spray dry method with PLGA of MW equal to 1.7x10
4
. The morphology of 
the microparticles from the spray dry method was found to be spherical and smooth, 
however small pores were observed on the surface of TMZ loaded microparticles as 
shown in Fig. 3.5 (b). The microparticles prepared with PLGA of higher MW were 
aggregated and lost the spherical shape, which is in agreement with the literature that 
states that microparticle produced with high molecular weight PLGA tend to lose the 
spherical shape and form fibrous particles (Seong et al., 2003; Lee et al., 2008). No 
morphological difference was observed between the microparticles of TMZ and Patrin-
2. There were a few large particles, which lost their spherical shape. It may have been 
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that as indicated in a recent study that during spraying of the solution some droplets 
may have slightly different sizes and the particles formed from such droplets could 
shrink due to evaporation of the solvent during the drying process (Pamujula et al., 
2004). However, the particle size distribution of the microparticles of both compounds 
was reproducible (Wang and Wang, 2003). 
4.6 Dissolution techniques 
The dispersion and dialysis methods were used to monitor the release of TMZ and 
Patrin-2 from the PLGA microparticles and to compare the in vitro release of TMZ and 
Patrin-2 (Shazly et al., 2008). An in vitro release profile can reveal basic information on 
the structural properties of the formulation as well as on possible interactions between 
drug and polymer and their effectiveness on the rate and mechanism of drug release 
(Washington, 1990). Such information is important in facilitating a scientific approach 
to the design and development of sustained drug delivery systems with specific 
properties (D’Souza and DeLuca, 2006). 
4.6.1. Dispersion Method used for determination of release of TMZ and Patrin-2 
from the PLGA microparticles. 
The release profiles of both TMZ and Patrin-2 from PLGA microparticles were 
monitored in to PBS, pH 7.4 at 37 ± 0.5 °C was carried out. From the release profiles it 
was observed that for TMZ loaded PLGA microparticles, there was an initial burst 
release of TMZ during the first six hours, followed by a decrease in the release of TMZ 
(Fig. 3.6). As observed from % cumulative release, 100 % release of TMZ was observed 
at 0.5 hr which is 407.06 µg (Refer table 3.18). However, the total amount of TMZ 
theoretically present in TMZ loaded PLGA microparticles at the beginning of the         
in vitro release was 1200 µg (Refer to EE % in table 3.17). Similarly from the release 
profile of Patrin-2 loaded PLGA microparticles, an initial burst release of Patrin-2 was 
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observed followed by a small amount of release of Patrin-2 (Fig. 3.7).The % cumulative 
release of Patrin-2 was calculated to be 100 % at 120 hr which is 196.16 µg in 
concentration (Table 3.19) however, the total amount of Patrin-2 release theoretically 
should have been 1500 µg (Refer to EE % in table 3.17). The initial burst release of 
TMZ and Patrin-2 might be due to diffusion of drug particles present on the surface of 
microparticles as well as the release of the encapsulated (Bodmeier and Chen, 1988; 
Shazly et al., 2008). Also the possible reason for the results obtained could be the 
degradation products formed of both the compounds at 37 °C due to which the expected 
amount of the drugs was not possible to calculate. 
As mentioned in section 1.5.4 the release of the drug from the polymer occurs in 
different phases, rapid release of the drug sometimes occurs due to pore formation, if 
the drug is bonded weakly to the polymer surface it is released with an initial burst. 
Initial burst release phase also occurs sometimes due to bulk degradation of the polymer 
(Allemann et al., 1993; Polakovic et al., 1999; Panyam et al., 2004; Liu et al., 2005; 
Tamber et al., 2005). If the bulk degradation of the polymer is made to exhibit surface 
degradation or layer-by-layer degradation, the polymer could present a promising 
control release of the drug also termed as sustained release (Conte et al., 1993;       
Abdul and Poddar, 2004; Chen et al., 2005; Loo et al., 2005; Frank et al., 2005;         
Loo et al., 2010). The fast release rate of TMZ could be due to its high affinity for 
water, using a more hydrophobic polymer PLGA 85:15 might support a much slower 
release rate than PLGA 75:25 used in this study (Lee et al., 2008). In previous studies it 
has been proved that the use of different monomer ratios of copolymer have helped to 
alter the in vitro release of the drug (Zhao et al., 2010). Other factors such as pH of the 
medium and porous surface might be responsible for the initial rapid release of TMZ 
and Patrin-2. The pH of the dissolution medium affects the drug significantly and may 
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be responsible for the rapid burst effect (O’Hara and Hickey, 2000). The differences in 
particle shape can also be a contributing factor to the high initial release of the spray 
dried particles (Pavanetto et al., 1992; Lalla and Sapna, 1993). In the previous studies, it 
has been demonstrated that particle porosity was found to be a greater determinant of 
total surface area than gross morphology (Pavanetto et al., 1992). One of the reasons for 
a decrease in concentration i.e. when TMZ was not been detected could be due to the 
rapid degradation of TMZ in PBS at pH 7.4. From our stability studies in section 4.2 
and data from others, it might be difficult to monitor the total amount of drug being 
released when degradation takes place (Wagenaar and Muller, 1994;                      
Zhang and Gao, 2007). This theory could apply to both TMZ and Patrin-2. However, 
sometimes the release pattern of the drug is also dependent not only on the diffusion of 
the drug through the matrix of the polymer but also on the degradation rate of the 
polymer (Schwendeman et al., 1996). For Patrin-2 an initial burst release with a 
continuous slow release was observed, again this could be either due to degradation of 
the compound in PBS at pH 7.4 or could be that the compound was in the lag phase and 
may be the monitoring should have been conducted for a longer period of time         
(Loo et al., 2010). A difference in the release pattern could have occurred due to early 
matrix erosion of the polymer, however, human error has not been ruled out 
(Spenlehauer et al., 1989; O’Hara and Hickey, 2000). The stage when there is no drug 
released is termed the lag phase where the drug is not diffusing out of the polymer and 
can be overcome by treating the sample with radiation (e-beam) which modifies the 
physical properties of the polymer and thereby reduces the lag phase (Miao et al., 2009; 
Loo et al.,  2010). 
 
121 
 
4.6.2 Dialysis Bag Method used for determination of release of TMZ and Patrin-2 
from the PLGA microparticles. 
The release profiles of TMZ and Patrin-2 from PLGA microparticles in to PBS, pH 7.4 
at 37 ± 0.5 °C was carried out. At predetermined time intervals (0.5, 1, 2, 4, 6, 12, 24, 
48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312 and 336 hr) an aliquot of 1 ml of 
the dispersion was withdrawn and replaced with 1 ml of PBS. The results were analysed 
using HPLC, however, the peak area obtained was too low to carry out the cumulative 
amount release calculation. The result obtained from the control was also too low. In the 
dialysis method the loaded microparticles were separated from the dissolution media by 
the dialysis membrane. The passage of the compound occurs through the membrane into 
the dissolution media and the sample is withdrawn for analysis (Berthold et al., 1996). 
The low concentration of the compound measured could have been due to the type of 
dialysis bag used was not suitably matched for the compounds for this reason 
sometimes compound takes longer time to diffuse out of the membrane                
(Larsen et al., 2000). This draw back could possibly be overcome by using varying MW 
exclusion cutoffs dialysis bags in the future studies to determine a suitable MW cut off 
range of the dialysis bag (Park et al., 1995). Some studies have reported that low 
concentration of drugs released could be attributed to equilibration with the outer 
dissolution media being slow because of the small membrane surface area available for 
the drug to transport (D’Souza and DeLuca, 2005). Slow equilibration causes 
limitations in accurate analysis of initial drug levels being released (Diaz et al., 1999). 
These disadvantages could be overcome by using a commercial dialysis setup which has 
a large surface area for facilitation of drug transport (D’Souza and DeLuca, 2005).       
In vitro analysis revealed that slower rates and incomplete drug release is sometimes 
observed when using a membrane system for dissolution tests (Gido et al., 1993). 
Previously studies have been undertaken to reduce the time span of the in vitro release 
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experiments, certain factors were taken into consideration for this purpose like addition 
of preservatives and impose certain limitations on the method such as compatibility of 
the constituents of the release device like membrane and its stability                   
(Burgess et al., 2002). Thus short term release experiments might be more reliable for 
quality analysis purposes. Some alterations in the conditions might help in accelerating 
the release of the compound from the membrane such conditions include elevated 
temperature, altering pH and use of surfactants (D’Souza and DeLuca, 2006). 
In comparison of the dissolution techniques based on the results obtained, the dispersion 
method proved to be better than the dialysis method, similarly in previous literature 
dispersion method was found to be better than dialysis method, however as both the 
methods were not completely explored and due to degradation of the drugs taking place 
it is not concluded as which method would have been better (Shazly et al., 2008).  The 
reasons for obtaining such lower values in the dialysis technique consists of certain 
limitations such as the outer media is stirred, however, the media inside the dialysis bag 
is not stirred accurately and sometimes it is subjected to accumulation of the polymer or 
the drug on the surface of the dialysis bag making the release process slower (Park et 
al., 1995). An additional limitation in this procedure of drug release is when the drug 
strongly binds to the polymer or membrane, however, this can be all evicted to some 
degree by sampling and buffer replacement (Kinget et al., 1979). 
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CONCLUSION  
Validated HPLC methods were used for the analysis of both TMZ and Patrin-2. TMZ is 
known to be effective in patients that lack MGMT activity since MGMT counteracts the 
effect of TMZ by removing the methyl group (originally added by temozolomide). 
Patrin-2 is used to counteract the effect of MGMT and thus enhances the activity of 
TMZ. Stability tests were carried out to determine whether or not TMZ and Patrin-2 
could be combined, however, degradation was observed on analysis of the combined 
mixture and therefore the work involved formulating these two actives in drug delivery 
systems separately and not in combination. 
TMZ loaded liposomes were prepared using different ratios of phospholipid 
individually and in combination with cholesterol/stearic acid. A combination of 
phospholipon 90H and cholesterol  at a ratio of 1:2:2 was found to be more effective in 
encapsulating TMZ as compared to other phospholipids such as                                     
lα-phosphatidylcholine, DSPC, DMPC and lecithin using freeze-thaw and       
dehydration-rehydration methods. It was found that the EE % varied depending on the 
type of lipid used. From the particle size analysis, it was noted that with an increase in 
concentration of certain lipids with the addition cholesterol, a slight increase in the 
average particle size was observed in both methods. Of the two methods used in the 
study involving the encapsulation of TMZ into liposomes the dehydration-rehydration 
method was found to be favoured since a significant increase in encapsulated ratio of 
1:2:2 occurred when was used with TMZ, phospholipon 90H and cholesterol. 
Two methods were used for preparing TMZ loaded PLGA microparticles namely 
emulsifying solvent evaporation and spray dry methods. The EE % obtained for the 
emulsifying solvent evaporation method was found to be too low to be considered, 
however, the spray dry method gave a significantly high EE %. The spray dry method 
used for the preparation of Patrin-2 loaded PLGA microparticles also resulted in a 
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significantly high EE %. The SEM of the microparticles showed that the microparticles 
were smooth and spherical, however some TMZ loaded microparticles showed pore 
formation.  From the findings it can be concluded that the lower the MW of PLGA used 
the higher the EE % in both methods. From the results one can conclude that, TMZ and 
Partin-2 were successfully encapsulated into PLGA microparticles using the spray dry 
method. 
To study the release profile of TMZ and Patrin-2 from the PLGA microparticles two 
methods were carried out namely the dispersion and dialysis bag diffusion method.  The 
dispersion method was found to be more efficient and reliable, however as both the 
methods were not completely explored it is not concluded as which method would have 
been better. TMZ and Patrin-2 showed an initial burst release, however TMZ later 
showed a decrease in concentration over a period of time while Patrin-2 showed a slow 
release with a steady increase in concentration. Both compounds did not show complete 
release from the microparticle in expected concentration which could be due to 
degradation of the drug taking place at the set temperature and pH, however future work 
could focus on improving the release of these compounds by altering the hydrophobic 
nature of the PLGA by varying the copolymer monomer ratio.  
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FUTURE PROSPECTS 
Based on the results obtained from the current research, the spray dry method was found 
to give the highest EE % for TMZ and Partin-2, however in order to achieve a higher 
EE % different solvent systems such as dichloromethane or chloroform could be 
investigated or the calculations of determining the EE% should be altered which would 
give higher encapsulation i.e. the amount of TMZ obtained from the microparticles 
using the HPLC should be compared with the amount of TMZ that could be 
theoretically present in the same amount of microparticles weighed out. Different 
monomer ratios of copolymer of PLGA consisting of greater hydrophobic polymers 
such as PLGA 85:15 of different molecular weights as well as PLGA polymers of MW 
less than 1.7x10
4
 Da could be investigated. The use of hydrophobic PLGA polymers 
may also enhance release profiles of TMZ and Patrin-2. Lower MW PLGA could be 
used to accelerate the release pattern of Patrin-2. The pH of the dissolution medium 
affects the drug significantly and is responsible for the burst effect. Altering the pH and 
the use of surfactants could also be included in a study. For the dialysis bag diffusion 
technique, different dialysis bags with varying MW’s could be investigated to find 
which would be most suitable in assisting the release of TMZ and Patrin-2. The 
microparticles could also be treated with radiation (e-beam) for faster release and 
modification in the technique by increasing the surface area of the dialysis bag available 
for the drug to diffuse out of the membrane might also enhance the release pattern of the 
drug. 
The viabilities of treated and untreated glioma cells could be determined using the 
standard MTT and ATP assays. To evaluate the cytotoxicity of TMZ loaded liposomes, 
TMZ and Patrin-2 loaded microparticles should be tested on glioma cell lines and their 
effect should be compared with the cytotoxicity of TMZ and Patrin-2 applied 
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separately. The effect of PLGA microparticles should also be tested on the glioma cell 
lines. 
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Appendix 1 
Validation of HPLC system for Temozolomide (TMZ) 
 
Figure 6.1 HPLC chromatogram for TMZ (0.1 mg/ml) (n = 3). 
 
 
 
Figure 6.2 HPLC chromatogram for TMZ (0.08 mg/ml) (n = 3). 
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Figure 6.3 HPLC chromatogram for TMZ (0.06 mg/ml) (n = 3). 
 
 
 
Figure 6.4 HPLC chromatogram for TMZ (0.04 mg/ml) (n = 3). 
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Figure 6.5 HPLC chromatogram for TMZ (0.02 mg/ml) (n = 3). 
 
 
Figure 6.6 HPLC chromatogram for TMZ (0.01 mg/ml) (n = 3). 
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Figure 6.7 HPLC chromatogram for TMZ (0.005 mg/ml) (n = 3). 
  
 
 
 
Figure 6.8 HPLC chromatogram for TMZ (0.0025 mg/ml) (n = 3). 
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Figure 6.9 HPLC chromatogram for TMZ (0.00125 mg/ml) (n = 3). 
 
 
 
Figure 6.10 HPLC chromatogram for TMZ (0.000625 mg/ml) (n = 3). 
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Figure 6.11 HPLC chromatogram for TMZ (0.000312 mg/ml) (n = 3). 
 
 
Figure 6.12 HPLC chromatogram for TMZ (0.000156 mg/ml) (n = 3). 
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Figure 6.13 HPLC chromatogram for reproducibility of TMZ (0.02 mg/ml) (n=6). 
 
 
 
Figure 6.14 HPLC chromatogram for repeatability of TMZ (0.02 mg/ml) (n=6). 
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 Figure 6.16 HPLC chromatogram showing LOD for TMZ (0.000039 mg/ml) (n = 3). 
 
 
Figure 6.15 HPLC chromatogram showing LOQ for TMZ (0.0000781 mg/ml) (n=6). 
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Appendix 2 
Validation of HPLC system for Patrin-2 
 
Figure 6.17 HPLC chromatogram for Patrin-2 (0.1 mg/ml) (n = 3). 
 
 
 
 
Figure 6.18 HPLC chromatogram for Patrin-2 (0.08 mg/ml) (n = 3). 
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Figure 6.19 HPLC chromatogram for Patrin-2 (0.06 mg/ml) (n = 3). 
 
 
 
Figure 6.20 HPLC chromatogram for Patrin-2 (0.04 mg/ml) (n = 3). 
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Figure 6.21 HPLC chromatogram for Patrin-2 (0.02 mg/ml) (n = 3). 
 
 
Figure 6.22 HPLC chromatogram for Patrin-2 (0.01 mg/ml) (n = 3). 
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Figure 6.22 HPLC chromatogram for Patrin-2 (0.005 mg/ml) (n = 3). 
 
 
 
Figure 6.23 HPLC chromatogram for Patrin-2 (0.0025 mg/ml) (n = 3). 
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Figure 6.24 HPLC chromatogram for Patrin-2 (0.00125 mg/ml) (n = 3). 
 
 
 
Figure 6.25 HPLC chromatogram for Patrin-2 (0.000625 mg/ml) (n = 3). 
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Figure 6.26 HPLC chromatogram for Patrin-2 (0.000312 mg/ml) (n = 3). 
 
 
Figure 6.27 HPLC chromatogram for Patrin-2 (0.000156 mg/ml) (n = 3). 
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Figure 6.28 HPLC chromatogram for repeatability of Patrin-2 (0.02 mg/ml) (n=6). 
 
Figure 6.29 HPLC chromatogram for reproducibility of Patrin-2 (0.02 mg/ml) (n=6). 
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Figure 6.31 HPLC chromatogram for LOD of Patrin-2 (0.000039 mg/ml) (n = 3). 
 
 
Figure 6.30 HPLC chromatogram for LOQ of Patrin-2 (0.0000781 mg/ml) (n=6). 
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Appendix 3 
Stability test for TMZ and Patrin-2 
 
Figure 6.32 HPLC chromatogram for the compatibility of TMZ and Patrin-2 at a concentration 
of 0.05 mg/ml in PBS and ethanol (ratio 8:2) solution stored for 72 hr at 25°C (n = 3). 
 
Figure 6.33 HPLC chromatogram for the compatibility of TMZ and Patrin-2 at a concentration 
of 0.05 mg/ml in PBS and ethanol (ratio 8:2) solution stored for 288 hr at 25°C (n = 3). 
 
 
 
 
 
161 
 
 
Figure 6.34 HPLC chromatogram for the compatibility of TMZ and Patrin-2 at a concentration 
of 0.05 mg/ml in PBS and ethanol (ratio 8:2) solution stored for 72 hr at 37°C (n = 3). 
 
 
 
 
Figure 6.35 HPLC chromatogram for the compatibility of TMZ and Patrin-2 at a concentration 
of 0.05 mg/ml in PBS and ethanol (ratio 8:2) solution stored for 72 hr at 50°C (n = 3). 
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Figure 6.36 HPLC chromatogram for the compatibility of TMZ and Patrin-2 at a concentration 
of 0.05 mg/ml in PBS and ethanol (ratio 8:2) solution stored for 288 hr at 50°C (n = 3). 
 
 
 
 
Figure 6.37 HPLC chromatogram for the dry sample reaction carried out to determine the 
compatibility of TMZ and Patrin-2 at a concentration of 0.05 mg/ml in PBS and ethanol (ratio 
8:2) (n = 3). 
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Appendix 4 
Calculation of EE % for TMZ loaded liposomes: 
1) Freeze-Thaw method 
                                    
                                   EE % = ADa   × 100 
                                                   ADb 
ADb → mean peak area obtained for TMZ in liposome before washing with PBS 
 ADa → mean peak area obtained for TMZ in liposome after washing with PBS  
 
ADa = 23.025 
ADb = 199.43 
EE % = 23.025 × 100 
  199.43 
 
= 11.54% 
 
 
2) Dehydration-Rehydration method 
                                   
                                   EE % = ADa   × 100 
                                                   ADb 
 
 ADb → mean peak area obtained for TMZ in liposome before washing with PBS 
 ADa → mean peak area obtained for TMZ in liposome after washing with PBS  
                                    
ADa = 163.12 
ADb = 611.01 
EE % = 163.12  × 100 
 611.01 
 
= 26.69% 
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Calculation of EE % for TMZ and Patrin-2 loaded PLGA microparticles: 
1) Emulsifying-solvent evaporation method for preparation of TMZ loaded 
microparticles. 
                                    
                                   EE % = Dm   × 100 
                                                   Dt 
  
 Dm → mean peak area obtained for TMZ in microparticle 
 Dt → mean peak area obtained for standard solution of TMZ 
 
Dm = 178.83 
Dt = 6456.41 
EE % = 178.83  × 100 
   6456.41 
 
= 2.76 % 
 
 
2) Spray dry method for preparation of TMZ loaded microparticles. 
                                   
                                   EE % = Dm   × 100 
                                                   Dt 
    
   Dm → mean peak area obtained for TMZ in microparticle 
      Dt → mean peak area obtained for standard solution of TMZ 
 
Dm = 5161.22 
Dt = 8023.08 
EE % = 5161.22  × 100 
8023.08 
 
= 64.32 % 
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3) Spray dry method for preparation of Patrin-2 loaded microparticles. 
                                   
                                   EE % = Dm   × 100 
                                                    Dt 
   
    Dm → mean peak area obtained for Patrin-2 in microparticle 
      Dt → mean peak area obtained for standard solution of Patrin-2 
                                    
Dm = 2619.75 
Dt = 3825.92 
EE % = 2619.75  × 100 
3825.92 
 
= 68.47 % 
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Calculation of cumulative mass release (µg) for TMZ loaded PLGA microparticle: 
 
T1 = T1 conc (µg/ml) * X 
T2 = (T2 conc (µg ml) * X) + T1 cumulative mass release-(T1 conc (µg /ml)* Y) 
T3 = (T3 conc (µg /ml) * X) + T2 cumulative mass release-(T2 conc (µg /ml)* Y) 
T4 = and so on… 
 
T= Sample collection timepoint 
X= Tolal volume of release medium (i.e. 25ml in this study) 
Y= Tolal volume of release medium-Sampling volume (i.e. 25ml-1ml=24ml) 
 
Calculations: 
T1  = 16.28 × 25 = 407.06 
T2 = (15.07 × 25) + 407.06 - (16.28 × 24) = 393.22 
Similarly the calculations were carried out for the remaining samples. 
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Calculation of cumulative mass release (µg) for Patrin-2 loaded PLGA 
microparticle: 
T1  = T1 conc (µg /ml) * X 
T2 = (T2 conc (µg /ml) * X) + T1 cumulative mass release-(T1 conc (µg /ml)* Y) 
T3 = (T3 conc (µg /ml) * X) + T2 cumulative mass release-(T2 conc (µg /ml)* Y) 
T4 = and so on… 
 
T= Sample collection timepoint 
X= Tolal volume of release medium (i.e. 25ml in this study) 
Y= Tolal volume of release medium-Sampling volume (i.e. 25ml-1ml=24ml) 
 
Calculations: 
T1 = 4.82 × 25 = 120.56 
T2 = (4.85 × 25) + 120.56 - (4.82 × 24) = 126.14 
Similarly the calculations were carried out for the remaining samples. 
 
 
 
 
